

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 0-16211

DENTSPLY International Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

39-1434669
(I.R.S. Employer
Identification No.)

221 West Philadelphia Street, York, PA
(Address of principal executive offices)

17405-2558
(Zip Code)

(717) 845-7511
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer" and "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: At October 22, 2014, DENTSPLY International Inc. had 141,529,741 shares of Common Stock outstanding, with a par value of \$.01 per share.

DENTSPLY International Inc.

TABLE OF CONTENTS

| <u>PART I</u> | <u>FINANCIAL INFORMATION</u> | <u>Page</u> |
|-----------------------|--|--------------------|
| <u>Item 1</u> | <u>Financial Statements (unaudited)</u> | <u>3</u> |
| | <u>Consolidated Statements of Operations</u> | <u>3</u> |
| | <u>Consolidated Statements of Comprehensive Income</u> | <u>4</u> |
| | <u>Consolidated Balance Sheets</u> | <u>5</u> |
| | <u>Consolidated Statements of Cash Flows</u> | <u>6</u> |
| | <u>Consolidated Statements of Changes in Equity</u> | <u>7</u> |
| | <u>Notes to Unaudited Interim Consolidated Financial Statements</u> | <u>8</u> |
| <u>Item 2</u> | <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>35</u> |
| <u>Item 3</u> | <u>Quantitative and Qualitative Disclosures About Market Risk</u> | <u>51</u> |
| <u>Item 4</u> | <u>Controls and Procedures</u> | <u>51</u> |
| <u>PART II</u> | <u>OTHER INFORMATION</u> | |
| <u>Item 1</u> | <u>Legal Proceedings</u> | <u>52</u> |
| <u>Item 1A</u> | <u>Risk Factors</u> | <u>52</u> |
| <u>Item 2</u> | <u>Unregistered Sales of Securities and Use of Proceeds</u> | <u>52</u> |
| <u>Item 6</u> | <u>Exhibits</u> | <u>53</u> |
| | <u>Signatures</u> | <u>53</u> |

PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements

**DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share amounts)

(unaudited)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|----------------------------------|------------|---------------------------------|--------------|
| | 2014 | 2013 | 2014 | 2013 |
| Net sales | \$ 708,240 | \$ 704,018 | \$ 2,203,579 | \$ 2,197,112 |
| Cost of products sold | 320,176 | 327,601 | 996,841 | 1,017,539 |
| Gross profit | 388,064 | 376,417 | 1,206,738 | 1,179,573 |
| Selling, general and administrative expenses | 275,980 | 269,165 | 859,943 | 852,763 |
| Restructuring and other costs | 2,503 | 2,231 | 4,538 | 5,065 |
| Operating income | 109,581 | 105,021 | 342,257 | 321,745 |
| Other income and expenses: | | | | |
| Interest expense | 12,665 | 11,442 | 35,418 | 38,170 |
| Interest income | (1,391) | (2,138) | (4,570) | (6,556) |
| Other expense (income), net | 791 | 1,581 | 1,754 | 8,723 |
| Income before income taxes | 97,516 | 94,136 | 309,655 | 281,408 |
| Provision for income taxes | 21,283 | 13,187 | 69,831 | 39,599 |
| Equity in net (loss) income of unconsolidated affiliated company | (967) | (83) | (1,624) | 320 |
| Net income | 75,266 | 80,866 | 238,200 | 242,129 |
| Less: Net (loss) income attributable to noncontrolling interests | (7) | 1,015 | 56 | 3,366 |
| Net income attributable to DENTSPLY International | \$ 75,273 | \$ 79,851 | \$ 238,144 | \$ 238,763 |
| Earnings per common share: | | | | |
| Basic | \$ 0.53 | \$ 0.56 | \$ 1.68 | \$ 1.67 |
| Diluted | \$ 0.52 | \$ 0.55 | \$ 1.65 | \$ 1.65 |
| Weighted average common shares outstanding: | | | | |
| Basic | 141,766 | 142,421 | 141,869 | 142,705 |
| Diluted | 144,286 | 144,698 | 144,289 | 144,952 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(unaudited)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Net income | \$ 75,266 | \$ 80,866 | \$ 238,200 | \$ 242,129 |
| Other comprehensive income (loss), net of tax: | | | | |
| Foreign currency translation adjustments | (198,622) | 140,374 | (227,297) | 52,118 |
| Net gain (loss) on derivative financial instruments | 35,898 | (31,997) | 38,095 | (17,241) |
| Net unrealized holding gain (loss) on available-for-sale securities | 3,558 | (1,916) | (245) | (10,905) |
| Pension liability adjustments | 3,865 | (1,692) | 5,006 | 1,624 |
| Total other comprehensive income (loss), net of tax | (155,301) | 104,769 | (184,441) | 25,596 |
| Total comprehensive (loss) income | (80,035) | 185,635 | 53,759 | 267,725 |
| Less: Comprehensive (loss) income attributable to noncontrolling interests | (252) | 2,666 | (392) | 4,866 |
| Comprehensive (loss) income attributable to DENTSPLY International | \$ (79,783) | \$ 182,969 | \$ 54,151 | \$ 262,859 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(unaudited)

| | September 30, 2014 | December 31, 2013 |
|---|---------------------|---------------------|
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 97,652 | \$ 74,954 |
| Accounts and notes receivables-trade, net | 476,856 | 472,802 |
| Inventories, net | 422,485 | 438,559 |
| Prepaid expenses and other current assets, net | 260,708 | 157,487 |
| Total Current Assets | 1,257,701 | 1,143,802 |
| Property, plant and equipment, net | 606,924 | 637,172 |
| Identifiable intangible assets, net | 710,112 | 795,323 |
| Goodwill, net | 2,160,696 | 2,281,596 |
| Other noncurrent assets, net | 148,628 | 220,154 |
| Total Assets | \$ 4,884,061 | \$ 5,078,047 |
| Liabilities and Equity | | |
| Current Liabilities: | | |
| Accounts payable | \$ 128,233 | \$ 132,789 |
| Accrued liabilities | 443,516 | 339,308 |
| Income taxes payable | 47,567 | 14,446 |
| Notes payable and current portion of long-term debt | 115,253 | 309,862 |
| Total Current Liabilities | 734,569 | 796,405 |
| Long-term debt | 1,165,566 | 1,166,178 |
| Deferred income taxes | 215,482 | 238,394 |
| Other noncurrent liabilities | 272,200 | 299,096 |
| Total Liabilities | 2,387,817 | 2,500,073 |
| Commitments and contingencies | | |
| Equity: | | |
| Preferred stock, \$.01 par value; .25 million shares authorized; no shares issued | — | — |
| Common stock, \$.01 par value; 200.0 million shares authorized; 162.8 million shares issued at September 30, 2014 and December 31, 2013 | 1,628 | 1,628 |
| Capital in excess of par value | 227,027 | 255,272 |
| Retained earnings | 3,305,448 | 3,095,721 |
| Accumulated other comprehensive loss | (253,055) | (69,062) |
| Treasury stock, at cost, 21.1 million and 20.5 million shares at September 30, 2014 and December 31, 2013, respectively | (785,940) | (748,506) |
| Total DENTSPLY International Equity | 2,495,108 | 2,535,053 |
| Noncontrolling interests | 1,136 | 42,921 |
| Total Equity | 2,496,244 | 2,577,974 |
| Total Liabilities and Equity | \$ 4,884,061 | \$ 5,078,047 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
(unaudited)

| | Nine Months Ended September 30, | |
|--|---------------------------------|------------------|
| | 2014 | 2013 |
| Cash flows from operating activities: | | |
| Net income | \$ 238,200 | \$ 242,129 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation | 63,048 | 61,545 |
| Amortization | 36,430 | 34,700 |
| Amortization of deferred financing costs | 3,517 | 3,842 |
| Deferred income taxes | 4,635 | (32,096) |
| Share-based compensation expense | 19,901 | 18,027 |
| Restructuring and other costs - non-cash | — | 843 |
| Stock option income tax benefit | (365) | (2,262) |
| Equity in loss (earnings) from unconsolidated affiliates | 1,624 | (320) |
| Other non-cash expense | 3,589 | 3,422 |
| Changes in operating assets and liabilities, net of acquisitions: | | |
| Accounts and notes receivable-trade, net | (30,916) | (65,455) |
| Inventories, net | (5,753) | (45,284) |
| Prepaid expenses and other current assets, net | (12,411) | 26,137 |
| Other noncurrent assets, net | 245 | 992 |
| Accounts payable | 1,947 | (25,099) |
| Accrued liabilities | 7,635 | 706 |
| Income taxes | 27,931 | 29,544 |
| Other noncurrent liabilities | 8,523 | 6,895 |
| Net cash provided by operating activities | 367,780 | 258,266 |
| Cash flows from investing activities: | | |
| Capital expenditures | (73,025) | (73,500) |
| Cash paid for acquisitions of businesses, net of cash acquired | (2,009) | (3,939) |
| Cash received from sale of business or product line | 1,371 | — |
| Cash received on derivatives contracts | 4,871 | 9,172 |
| Cash paid on derivatives contracts | (4,865) | (95,667) |
| Expenditures for identifiable intangible assets | (1,314) | (1,049) |
| Purchase of short-term investments | (2,271) | — |
| Liquidation of short-term investments | 1,136 | — |
| Purchase of Company-owned life insurance policies | (900) | — |
| Proceeds from sale of property, plant and equipment, net | 601 | 3,092 |
| Net cash used in investing activities | (76,405) | (161,891) |
| Cash flows from financing activities: | | |
| (Decrease) increase in short-term borrowings | (99,831) | 8,789 |
| Cash paid for treasury stock | (70,757) | (72,381) |
| Cash dividends paid | (27,927) | (25,895) |
| Cash paid for acquisition of noncontrolling interests of consolidated subsidiary | (33) | (8,960) |
| Proceeds from long-term borrowings | 114,070 | 174,628 |
| Repayments on long-term borrowings | (198,991) | (251,335) |
| Proceeds from exercised stock options | 18,733 | 48,350 |
| Excess tax benefits from share-based compensation | 365 | 2,262 |
| Cash received on derivative contracts | — | 21 |
| Cash paid on derivative contracts | — | (129) |
| Net cash used in financing activities | (264,371) | (124,650) |
| Effect of exchange rate changes on cash and cash equivalents | (4,306) | (1,199) |
| Net increase (decrease) in cash and cash equivalents | 22,698 | (29,474) |

| | | |
|--|------------------|------------------|
| Cash and cash equivalents at beginning of period | 74,954 | 80,132 |
| Cash and cash equivalents at end of period | <u>\$ 97,652</u> | <u>\$ 50,658</u> |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands)

(unaudited)

| | Common Stock | Capital in Excess of Par Value | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Total DENTSPLY International Equity | Noncontrolling Interests | Total Equity |
|--|--------------|--------------------------------|-------------------|--------------------------------------|----------------|-------------------------------------|--------------------------|--------------|
| Balance at December 31, 2012 | \$ 1,628 | \$ 246,548 | \$ 2,818,461 | \$ (144,200) | \$ (713,739) | \$ 2,208,698 | \$ 40,745 | \$ 2,249,443 |
| Net income | — | — | 238,763 | — | — | 238,763 | 3,366 | 242,129 |
| Other comprehensive income | — | — | — | 24,096 | — | 24,096 | 1,500 | 25,596 |
| Acquisition of noncontrolling interest | — | (3,926) | — | — | — | (3,926) | (5,034) | (8,960) |
| Exercise of stock options | — | (5,569) | — | — | 53,919 | 48,350 | — | 48,350 |
| Tax benefit from stock options exercised | — | 2,262 | — | — | — | 2,262 | — | 2,262 |
| Share based compensation expense | — | 18,027 | — | — | — | 18,027 | — | 18,027 |
| Funding of Employee Stock Ownership Plan | — | 959 | — | — | 3,698 | 4,657 | — | 4,657 |
| Treasury shares purchased | — | — | — | — | (72,381) | (72,381) | — | (72,381) |
| RSU distributions | — | (8,378) | — | — | 5,015 | (3,363) | — | (3,363) |
| RSU dividends | — | 230 | (230) | — | — | — | — | — |
| Cash dividends (\$0.18750 per share) | — | — | (26,742) | — | — | (26,742) | — | (26,742) |
| Balance at September 30, 2013 | \$ 1,628 | \$ 250,153 | \$ 3,030,252 | \$ (120,104) | \$ (723,488) | \$ 2,438,441 | \$ 40,577 | \$ 2,479,018 |

| | Common Stock | Capital in Excess of Par Value | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Total DENTSPLY International Equity | Noncontrolling Interests | Total Equity |
|--|--------------|--------------------------------|-------------------|--------------------------------------|----------------|-------------------------------------|--------------------------|--------------|
| Balance at December 31, 2013 | \$ 1,628 | \$ 255,272 | \$ 3,095,721 | \$ (69,062) | \$ (748,506) | \$ 2,535,053 | \$ 42,921 | \$ 2,577,974 |
| Net income | — | — | 238,144 | — | — | 238,144 | 56 | 238,200 |
| Other comprehensive loss | — | — | — | (178,463) | — | (178,463) | (448) | (178,911) |
| Acquisition of noncontrolling interest | — | (35,814) | — | (5,530) | — | (41,344) | (41,393) | (82,737) |
| Exercise of stock options | — | (3,274) | — | — | 22,007 | 18,733 | — | 18,733 |
| Tax benefit from stock options exercised | — | 365 | — | — | — | 365 | — | 365 |
| Share based compensation expense | — | 19,901 | — | — | — | 19,901 | — | 19,901 |
| Funding of Employee Stock Ownership Plan | — | 1,535 | — | — | 4,418 | 5,953 | — | 5,953 |
| Treasury shares purchased | — | — | — | — | (70,757) | (70,757) | — | (70,757) |
| RSU distributions | — | (11,201) | — | — | 6,898 | (4,303) | — | (4,303) |
| RSU dividends | — | 243 | (243) | — | — | — | — | — |
| Cash dividends (\$0.19875 per share) | — | — | (28,174) | — | — | (28,174) | — | (28,174) |
| Balance at September 30, 2014 | \$ 1,628 | \$ 227,027 | \$ 3,305,448 | \$ (253,055) | \$ (785,940) | \$ 2,495,108 | \$ 1,136 | \$ 2,496,244 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY International Inc. and Subsidiaries

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the United States Securities and Exchange Commission (“SEC”). The year-end consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY International Inc. and Subsidiaries (“DENTSPLY” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2013.

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended December 31, 2013, except as may be indicated below:

Accounts and Notes Receivable

The Company sells dental and certain healthcare products through a worldwide network of distributors and directly to end users. For customers on credit terms, the Company performs ongoing credit evaluations of those customers’ financial condition and generally does not require collateral from them. The Company establishes allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments based on historical averages of aged receivable balances and the Company’s experience in collecting those balances, customer specific circumstances, as well as changes in the economic and political environments. The Company records a provision for doubtful accounts, which is included in “Selling, general and administrative expenses” on the Consolidated Statements of Operations.

Accounts and notes receivables – trade, net are stated net of allowances for doubtful accounts and trade discounts, which were \$11.2 million at September 30, 2014 and \$14.7 million at December 31, 2013.

Marketable Securities

The Company’s marketable securities consist of corporate convertible bonds that are classified as available-for-sale in “Other noncurrent assets, net” on the Consolidated Balance Sheets as the instruments mature in December 2015. The Company determined the appropriate classification at the time of purchase and will re-evaluate such designation as of each balance sheet date. In addition, the Company reviews the securities each quarter for indications of possible impairment. If an impairment is identified, the determination of whether the impairment is temporary or other-than-temporary requires significant judgment. The primary factors that the Company considers in making this judgment include the extent and time the fair value of each investment has been below cost and the existence of a credit loss. If a decline in fair value is judged other-than-temporary, the basis of the securities is written down to fair value and the amount of the write-down is included as a realized loss in the Consolidated Statement of Operations. Changes in fair value are reported in accumulated other comprehensive income (“AOCI”).

The convertible element of the bonds has not been bifurcated from the underlying bonds as the element does not contain a net-settlement feature, nor would the Company be able to achieve a hypothetical net-settlement that would substantially place the Company in a comparable cash settlement position. As such, the derivative is not accounted for separately from the bond. The cash paid by the Company was equal to the face value of the bonds issued, and therefore, the Company has not recorded any bond premium or discount on acquiring the bonds. The fair value of the bonds was \$65.5 million and \$70.0 million at September 30, 2014 and December 31, 2013, respectively. At September 30, 2014 and December 31, 2013, an unrealized holding gain of \$12.5 million and \$12.7 million, respectively, on available-for-sale securities, net of tax, has been recorded in AOCI.

New Accounting Pronouncements

In March 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-05, “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” This newly issued accounting standard requires a cumulative translation adjustment (“CTA”) attached to the parent’s investment in a

foreign entity should be released in a manner consistent with the derecognition guidance on investment entities. Thus the entire amount of CTA associated with the foreign entity would be released when there has been a sale of a subsidiary or group of net assets within a foreign entity and the sale represents a complete liquidation of the investment in the foreign entity, a loss of a controlling financial interest in an investment in a foreign entity, or step acquisition for a foreign entity. The Company adopted this accounting standard for the quarter ended March 31, 2014. The adoption of this standard did not materially impact the Company's financial position or results of operations.

In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." The newly issued accounting standard requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. Under the new standard, unrecognized tax benefits will be netted against all available same-jurisdiction losses or other tax carryforwards that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefit. The Company adopted this accounting standard for the quarter ended March 31, 2014. The adoption of this standard did not materially impact the Company's financial position or results of operations.

In April 2014, the FASB issued ASU No. 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity." This newly issued accounting standard changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This standard will have the impact of reducing the frequency of disposals reported as discontinued operations, by requiring such a disposal to represent a strategic shift that has or will have a major effect on entity's operations and financial results. Additionally, existing provisions that prohibit an entity from reporting a discontinued operation if it has certain continuing cash flows or involvement with the component after a disposal are eliminated by this standard. The ASU also expands the disclosures for discontinued operations and requires new disclosures related to individually significant disposals that do not qualify as discontinued operations. This standard allows for early adoption and the Company expects to adopt this accounting standard no later than the quarter ended March 31, 2015. The adoption of this standard is not expected to materially impact the Company's financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". This newly issued accounting standard is intended to improve the reporting of revenue. The Company has not yet determined the impact from adoption of this new accounting pronouncement on the Company's financial position or results of operations. The Company expects to adopt this accounting standard for the quarter ended March 31, 2017. Early adoption is not permitted.

NOTE 2 – STOCK COMPENSATION

The following table represents total stock based compensation expense for non-qualified stock options, restricted stock units (“RSU”) and the tax related benefit for the three and nine months ended September 30, 2014 and 2013:

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-----------------|-------------------|------------------|
| | 2014 | 2013 | 2014 | 2013 |
| Stock option expense | \$ 2,148 | \$ 2,565 | \$ 6,651 | \$ 7,570 |
| RSU expense | 4,013 | 3,077 | 12,098 | 9,346 |
| Total stock based compensation expense | <u>\$ 6,161</u> | <u>\$ 5,642</u> | <u>\$ 18,749</u> | <u>\$ 16,916</u> |
| Total related tax benefit | <u>\$ 1,550</u> | <u>\$ 1,590</u> | <u>\$ 5,093</u> | <u>\$ 4,250</u> |

At September 30, 2014, the remaining unamortized compensation cost related to non-qualified stock options is \$11.5 million, which will be expensed over the weighted average remaining vesting period of the options, or approximately 1.6 years. At September 30, 2014, the unamortized compensation cost related to RSU is \$23.8 million, which will be expensed over the weighted average remaining restricted period of the RSU, or approximately 1.4 years.

The following table reflects the non-qualified stock option transactions from December 31, 2013 through September 30, 2014:

| (in thousands, except per share data) | Outstanding | | | Exercisable | | |
|---------------------------------------|--------------|---------------------------------|---------------------------|-------------|---------------------------------|---------------------------|
| | Shares | Weighted Average Exercise Price | Aggregate Intrinsic Value | Shares | Weighted Average Exercise Price | Aggregate Intrinsic Value |
| Balance at December 31, 2013 | 8,295 | \$ 35.04 | \$ 111,450 | 6,225 | \$ 33.67 | \$ 92,200 |
| Granted | 926 | 45.24 | | | | |
| Exercised | (581) | 32.25 | | | | |
| Cancelled | (5) | 45.15 | | | | |
| Forfeited | (25) | 40.88 | | | | |
| Balance at September 30, 2014 | <u>8,610</u> | \$ 36.31 | \$ 80,108 | 6,729 | \$ 34.57 | \$ 74,228 |

At September 30, 2014, the weighted average remaining contractual term of all outstanding options is approximately 5.5 years and the weighted average remaining contractual term of exercisable options is approximately 4.6 years.

The following table summarizes the unvested RSU transactions from December 31, 2013 through September 30, 2014:

| (in thousands, except per share data) | Shares | Weighted Average Grant Date Fair Value |
|---------------------------------------|------------------------------|--|
| | Balance at December 31, 2013 | 1,131 |
| Granted | 446 | 45.18 |
| Vested | (279) | 36.59 |
| Forfeited | (98) | 40.86 |
| Balance at September 30, 2014 | <u>1,200</u> | \$ 41.52 |

NOTE 3 – COMPREHENSIVE INCOME

During the quarter ended September 30, 2014, foreign currency translation adjustments included currency translation losses of \$201.8 million and gains on the Company's loans designated as hedges of net investments of \$9.0 million. During the quarter ended September 30, 2013, foreign currency translation adjustments included currency translation gains of \$141.4 million and losses of \$2.7 million on the Company's loans designated as hedges of net investments. During the nine months ended September 30, 2014, foreign currency translation adjustments included currency translation losses of \$227.2 million and gains on the Company's loans designated as hedges of net investments of \$5.9 million. During the nine months ended September 30, 2013, foreign currency translation adjustments included currency translation gains of \$40.8 million and gains on the Company's loans designated as hedges of net investments of \$9.8 million. These foreign currency translation adjustments were partially offset by movements on derivative financial instruments, which are discussed in Note 10, Financial Instruments and Derivatives.

The cumulative foreign currency translation adjustments included translation gains of \$17.1 million and \$249.9 million at September 30, 2014 and December 31, 2013, respectively, were offset by losses of \$103.0 million and \$108.9 million, respectively, on loans designated as hedges of net investments. These foreign currency translation adjustments were partially offset by movements on derivatives financial instruments, which are discussed in Note 10, Financial Instruments and Derivatives.

Changes in AOCI, net of tax, by component for the nine months ended September 30, 2014 and 2013:

| (in thousands) | Foreign Currency Translation Adjustments | Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges | Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges | Net Unrealized Holding Gain (Loss) on Available-for- Sale Securities | Pension Liability Adjustments | Total |
|---|--|--|---|--|----------------------------------|--------------|
| Balance at December 31, 2013 | \$ 140,992 | \$ (21,753) | \$ (151,114) | \$ 12,729 | \$ (49,916) | \$ (69,062) |
| Other comprehensive income (loss) before reclassifications | (221,319) | 4,498 | 27,619 | (245) | 3,611 | (185,836) |
| Amounts reclassified from accumulated other comprehensive income (loss) | — | 5,978 | — | — | 1,395 | 7,373 |
| Net (decrease) increase in other comprehensive income | (221,319) | 10,476 | 27,619 | (245) | 5,006 | (178,463) |
| Foreign currency translation related to acquisition of noncontrolling interests | (5,530) | — | — | — | — | (5,530) |
| Balance at September 30, 2014 | \$ (85,857) | \$ (11,277) | \$ (123,495) | \$ 12,484 | \$ (44,910) | \$ (253,055) |

| (in thousands) | Foreign Currency Translation Adjustments | Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges | Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges | Net Unrealized Holding Gain (Loss) on Available-for- Sale Securities | Pension Liability Adjustments | Total |
|---|--|--|---|--|----------------------------------|--------------|
| Balance at December 31, 2012 | \$ 54,302 | \$ (17,481) | \$ (125,661) | \$ 17,822 | \$ (73,182) | \$ (144,200) |
| Other comprehensive income (loss) before reclassifications | 50,618 | (3,562) | (14,408) | (10,905) | (1,195) | 20,548 |
| Amounts reclassified from accumulated other comprehensive income (loss) | — | 729 | — | — | 2,819 | 3,548 |
| Net increase (decrease) in other comprehensive income | 50,618 | (2,833) | (14,408) | (10,905) | 1,624 | 24,096 |
| Balance at September 30, 2013 | \$ 104,920 | \$ (20,314) | \$ (140,069) | \$ 6,917 | \$ (71,558) | \$ (120,104) |

Reclassifications out of accumulated other comprehensive income (expense) to the Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013:

(in thousands)

| Details about AOCI Components | Amounts Reclassified from AOCI | | Affected Line Item in the Statements of Operations |
|--|--|-------------------|---|
| | Three Months Ended September 30, 2014 | 2013 | |
| Gains and (losses) on derivative financial instruments: | | | |
| Interest rate swaps | \$ (929) | \$ (924) | Interest expense |
| Foreign exchange forward contracts | (2,191) | 460 | Cost of products sold |
| Foreign exchange forward contracts | (16) | (27) | SG&A expenses |
| Commodity contracts | (95) | (190) | Cost of products sold |
| | (3,231) | (681) | Net loss before tax |
| | 1,320 | 156 | Tax benefit |
| | \$ (1,911) | \$ (525) | Net of tax |
| Amortization of defined benefit pension and other postemployment benefit items: | | | |
| Amortization of prior service benefits | \$ 33 | \$ 34 | (a) |
| Amortization of net actuarial losses | (678) | (1,380) | (a) |
| | (645) | (1,346) | Net loss before tax |
| | 193 | 394 | Tax benefit |
| | \$ (452) | \$ (952) | Net of tax |
| Total reclassifications for the period | \$ (2,363) | \$ (1,477) | |

(a) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost for the three months ended September 30, 2014 and 2013 (see Note 8, Benefit Plans, for additional details).

(in thousands)

| Details about AOCI Components | Amounts Reclassified from AOCI | | Affected Line Item in the Statements of Operations |
|--|---------------------------------|-------------------|--|
| | Nine Months Ended September 30, | | |
| | 2014 | 2013 | |
| Gains and (losses) on derivative financial instruments: | | | |
| Interest rate swaps | \$ (2,785) | \$ (2,755) | Interest expense |
| Foreign exchange forward contracts | (5,487) | 1,589 | Cost of products sold |
| Foreign exchange forward contracts | (174) | (67) | SG&A expenses |
| Commodity contracts | (498) | 12 | Cost of products sold |
| | <u>(8,944)</u> | <u>(1,221)</u> | Net loss before tax |
| | 2,966 | 492 | Tax benefit |
| | <u>\$ (5,978)</u> | <u>\$ (729)</u> | Net of tax |
| Amortization of defined benefit pension and other postemployment benefit items: | | | |
| Amortization of prior service benefits | \$ 102 | \$ 101 | (b) |
| Amortization of net actuarial losses | (2,116) | (4,104) | (b) |
| | <u>(2,014)</u> | <u>(4,003)</u> | Net loss before tax |
| | 619 | 1,184 | Tax benefit |
| | <u>\$ (1,395)</u> | <u>\$ (2,819)</u> | Net of tax |
| Total reclassifications for the period | <u>\$ (7,373)</u> | <u>\$ (3,548)</u> | |

(b) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost for the nine months ended September 30, 2014 and 2013 (see Note 8, Benefit Plans, for additional details).

NOTE 4 – EARNINGS PER COMMON SHARE

The dilutive effect of outstanding non-qualified stock options and RSU is reflected in diluted earnings per share by application of the treasury stock method. The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2014 and 2013:

| Basic Earnings Per Common Share Computation (in thousands, except per share amounts) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-----------|-------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Net income attributable to DENTSPLY International | \$ 75,273 | \$ 79,851 | \$ 238,144 | \$ 238,763 |
| Weighted average common shares outstanding | 141,766 | 142,421 | 141,869 | 142,705 |
| Earnings per common share - basic | \$ 0.53 | \$ 0.56 | \$ 1.68 | \$ 1.67 |
| Diluted Earnings Per Common Share Computation (in thousands, except per share amounts) | | | | |
| Net income attributable to DENTSPLY International | \$ 75,273 | \$ 79,851 | \$ 238,144 | \$ 238,763 |
| Weighted average common shares outstanding | 141,766 | 142,421 | 141,869 | 142,705 |
| Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards | 2,520 | 2,277 | 2,420 | 2,247 |
| Total weighted average diluted shares outstanding | 144,286 | 144,698 | 144,289 | 144,952 |
| Earnings per common share - diluted | \$ 0.52 | \$ 0.55 | \$ 1.65 | \$ 1.65 |

The calculation of weighted average diluted shares outstanding excludes options to purchase 0.9 million and 1.2 million shares of common stock that were outstanding during the three and nine months ended September 30, 2014, respectively, because their effect would be antidilutive. There were 2.1 million and 2.7 million antidilutive shares of common stock outstanding during the three and nine months ended September 30, 2013, respectively.

NOTE 5 – BUSINESS ACQUISITIONS

Effective January 1, 2014, the Company recorded a liability for the contractual purchase of the remaining shares of one variable interest entity. The amount is preliminary and is based on the Company's best estimate of this obligation, which is subject to contractual adjustments. As a result, the Company recorded a reduction to additional paid in capital for the excess of the purchase price above the carrying value of the noncontrolling interest. The Company anticipates the cash outflow for this purchase to be later in 2014 or early in 2015.

NOTE 6 – SEGMENT INFORMATION

The Company has numerous operating businesses covering a wide range of dental and certain healthcare products and geographic regions, primarily serving the professional dental market. Professional dental products represented approximately 88% of sales in each of the three month periods ended September 30, 2014 and 2013, and 88% of sales for the nine month periods ended September 30, 2014 and 2013.

The operating businesses are combined into operating groups, which generally have overlapping product offerings, geographical presence, customer bases, distribution channels, and regulatory oversight. These operating groups are considered the Company's reportable segments as the Company's chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company's operations. The accounting policies of the segments are consistent with those described in the Company's most recently filed Form 10-K in the summary of significant accounting policies. The Company evaluates performance of the segments based on the groups' net third party sales, excluding precious metal content, and segment income. The Company defines net third party sales excluding precious metal content as the Company's net sales excluding the precious metal cost within the products sold, and this is considered a non-US GAAP measure. The

Company's exclusion of precious metal content in the measurement of net third party sales enhances comparability of performance between periods as it excludes the fluctuating market prices of the precious metal content. The Company defines segment income as net operating income before restructuring and other costs, interest expense, interest income, other expense (income), net and provision for income taxes. A description of the products and services provided within each of the Company's three reportable segments is provided below.

Significant interdependencies exist among the Company's operations in certain geographic areas. Inter-segment sales are at prices intended to provide a reasonable profit to the manufacturing unit after recovery of all manufacturing costs and to provide a reasonable profit for purchasing locations after coverage of marketing and general and administrative costs.

During the first quarter of 2014, the Company realigned reporting responsibilities for multiple locations as a result of changes to the management structure. The segment information below reflects the revised structure for all periods shown.

Dental Consumables and Certain International Businesses

This segment includes responsibility for the design and manufacture of the Company's chairside consumable products. It also has responsibilities for sales and distribution of certain small equipment and chairside consumable products in the United States, Germany and certain other European regions as well as responsibility for the sales and distribution of certain endodontic products in Germany and certain other European regions. In addition, this segment has responsibilities for sales and distribution of chairside consumable, endodontic and dental laboratory products in Australia.

Dental Specialty and Laboratory and Certain Global Distribution Businesses

This segment includes responsibility for the design, manufacture, sales and distribution of most of the Company's dental specialty products, including endodontic, orthodontic and implant products, in most regions of the world. In addition, this segment is responsible for the design, manufacture, sales and distribution of most of the Company's dental laboratory products. This segment is also responsible for the sales and distribution of most of the Company's other dental products, including most dental consumables, within certain European regions as well as Japan, Canada and Mexico, and the design, manufacture, worldwide distribution and sales of certain non-dental products, excluding urological and surgery-related products.

Healthcare and Emerging Markets Businesses

This segment is responsible for the worldwide design, manufacture, sales and distribution of the Company's healthcare products, primarily urological and surgery-related products, throughout most of the world. This segment also includes the responsibility for the sales and distribution of most of the Company's dental products, including most dental consumables, sold in Eastern Europe, Middle East, South America, Latin America, Asia (excluding Japan) and Africa.

The following tables set forth information about the Company's segments for the three and nine months ended September 30, 2014 and 2013:

Third Party Net Sales

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-------------------|---------------------|---------------------|
| | 2014 | 2013 | 2014 | 2013 |
| Dental Consumable and Certain International Businesses | \$ 182,885 | \$ 172,382 | \$ 540,601 | \$ 506,777 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 387,005 | 403,200 | 1,262,067 | 1,309,304 |
| Healthcare and Emerging Markets Businesses | 139,521 | 129,551 | 404,314 | 384,344 |
| All Other (a) | (1,171) | (1,115) | (3,403) | (3,313) |
| Total net sales | \$ 708,240 | \$ 704,018 | \$ 2,203,579 | \$ 2,197,112 |

(a) Includes amounts recorded at Corporate headquarters.

Third Party Net Sales, Excluding Precious Metal Content

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|------------|-------------------|--------------|
| | 2014 | 2013 | 2014 | 2013 |
| Dental Consumable and Certain International Businesses | \$ 182,811 | \$ 172,300 | \$ 540,363 | \$ 506,505 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 360,600 | 368,915 | 1,160,911 | 1,171,218 |
| Healthcare and Emerging Markets Businesses | 139,344 | 129,324 | 403,794 | 383,619 |
| All Other (b) | (1,171) | (1,115) | (3,403) | (3,313) |
| Total net sales, excluding precious metal content | 681,584 | 669,424 | 2,101,665 | 2,058,029 |
| Precious metal content of sales | 26,656 | 34,594 | 101,914 | 139,083 |
| Total net sales, including precious metal content | \$ 708,240 | \$ 704,018 | \$ 2,203,579 | \$ 2,197,112 |

(b) Includes amounts recorded at Corporate headquarters.

Inter-segment Net Sales

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-----------|-------------------|-----------|
| | 2014 | 2013 | 2014 | 2013 |
| Dental Consumable and Certain International Businesses | \$ 29,296 | \$ 30,154 | \$ 90,106 | \$ 91,757 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 42,689 | 47,161 | 143,407 | 139,598 |
| Healthcare and Emerging Markets Businesses | 3,851 | 3,611 | 9,797 | 10,188 |
| All Other (c) | 58,751 | 61,214 | 182,019 | 178,880 |
| Eliminations | (134,587) | (142,140) | (425,329) | (420,423) |
| Total | \$ — | \$ — | \$ — | \$ — |

(c) Includes amounts recorded at Corporate headquarters and one distribution warehouse not managed by named segments.

Segment Operating Income (Loss)

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-----------|-------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Dental Consumable and Certain International Businesses | \$ 69,135 | \$ 61,946 | \$ 193,791 | \$ 176,124 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 57,504 | 62,125 | 211,033 | 211,561 |
| Healthcare and Emerging Markets Businesses | 9,834 | 6,239 | 24,517 | 16,328 |
| All Other (d) | (24,389) | (23,058) | (82,546) | (77,203) |
| Segment operating income | 112,084 | 107,252 | 346,795 | 326,810 |

Reconciling Items:

| | | | | |
|-------------------------------|-----------|-----------|------------|------------|
| Restructuring and other costs | 2,503 | 2,231 | 4,538 | 5,065 |
| Interest expense | 12,665 | 11,442 | 35,418 | 38,170 |
| Interest income | (1,391) | (2,138) | (4,570) | (6,556) |
| Other expense (income), net | 791 | 1,581 | 1,754 | 8,723 |
| Income before income taxes | \$ 97,516 | \$ 94,136 | \$ 309,655 | \$ 281,408 |

(d) Includes the results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

Assets

| (in thousands) | September 30, 2014 | December 31, 2013 |
|--|---------------------|---------------------|
| Dental Consumable and Certain International Businesses | \$ 684,089 | \$ 683,965 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 3,133,070 | 3,364,190 |
| Healthcare and Emerging Markets Businesses | 862,659 | 925,742 |
| All Other (e) | 204,243 | 104,150 |
| Total | \$ 4,884,061 | \$ 5,078,047 |

(e) Includes the assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

NOTE 7 – INVENTORIES

Inventories are stated at the lower of cost or market. The cost of inventories determined by the last-in, first-out (“LIFO”) method at September 30, 2014 and December 31, 2013 were \$6.8 million and \$6.5 million, respectively. The cost of other inventories was determined by the first-in, first-out (“FIFO”) or average cost methods. If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at September 30, 2014 and December 31, 2013 by \$6.1 million and \$5.9 million, respectively.

The Company establishes reserves for inventory estimated to be obsolete or unmarketable. Assumptions about future demand and market conditions are considered when estimating these reserves. The inventory valuation reserves were \$37.5 million and \$34.2 million at September 30, 2014 and December 31, 2013, respectively.

Inventories, net of inventory valuation reserves, consist of the following:

| (in thousands) | September 30, 2014 | December 31, 2013 |
|----------------------------|--------------------|-------------------|
| Finished goods | \$ 273,773 | \$ 285,271 |
| Work-in-process | 66,831 | 67,718 |
| Raw materials and supplies | 81,881 | 85,570 |
| Inventories, net | \$ 422,485 | \$ 438,559 |

NOTE 8 – BENEFIT PLANS

The following sets forth the components of net periodic benefit cost of the Company’s defined benefit plans and for the Company’s other postemployment benefit plans for the three and nine months ended September 30, 2014 and 2013:

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|--------------------------------------|--------------------|-----------------|-------------------|------------------|
| | 2014 | 2013 | 2014 | 2013 |
| Defined Benefit Plans | | | | |
| Service cost | \$ 3,371 | \$ 3,728 | \$ 10,473 | \$ 11,113 |
| Interest cost | 2,742 | 2,486 | 8,468 | 7,408 |
| Expected return on plan assets | (1,339) | (1,252) | (4,117) | (3,729) |
| Amortization of prior service credit | (33) | (34) | (102) | (101) |
| Amortization of net actuarial loss | 699 | 1,292 | 2,116 | 3,840 |
| Curtailments and settlement gains | — | (680) | — | (1,305) |
| Net periodic benefit cost | \$ 5,440 | \$ 5,540 | \$ 16,838 | \$ 17,226 |

Other Postemployment Benefit Plans

| (in thousands) | Three Months Ended | | Nine Months Ended | |
|---|--------------------|---------------|-------------------|---------------|
| | 2014 | 2013 | 2014 | 2013 |
| Service cost | \$ 97 | \$ 61 | \$ 187 | \$ 184 |
| Interest cost | 118 | 122 | 398 | 364 |
| Amortization of net actuarial (gain) loss | (21) | 88 | — | 264 |
| Net periodic benefit cost | <u>\$ 194</u> | <u>\$ 271</u> | <u>\$ 585</u> | <u>\$ 812</u> |

The following sets forth the information related to the contributions to the Company's benefit plans for 2014:

| (in thousands) | Pension Benefits | Other Postemployment Benefits |
|---|------------------|-------------------------------|
| | | |
| Actual contributions through September 30, 2014 | \$ 8,967 | \$ 196 |
| Projected contributions for the remainder of the year | 3,310 | 306 |
| Total projected contributions | <u>\$ 12,277</u> | <u>\$ 502</u> |

NOTE 9 – RESTRUCTURING AND OTHER COSTS

Restructuring Costs

During the three and nine months ended September 30, 2014, the Company recorded net restructuring costs of \$2.5 million and \$4.5 million, respectively. During the three and nine months ended September 30, 2013, the Company recorded net restructuring costs of \$2.4 million and \$5.2 million, respectively. These costs are recorded in "Restructuring and other costs" in the Consolidated Statements of Operations and the associated liabilities are recorded in "Accrued liabilities" in the Consolidated Balance Sheets.

At September 30, 2014, the Company's restructuring accruals were as follows:

| (in thousands) | Severance | | | |
|-------------------------------|----------------------|-----------------|-----------------|-----------------|
| | 2012 and Prior Plans | 2013 Plans | 2014 Plans | Total |
| | | | | |
| Balance at December 31, 2013 | \$ 1,282 | \$ 5,764 | \$ — | \$ 7,046 |
| Provisions | 144 | 288 | 3,670 | 4,102 |
| Amounts applied | (691) | (3,877) | (679) | (5,247) |
| Change in estimates | (376) | (747) | (219) | (1,342) |
| Balance at September 30, 2014 | <u>\$ 359</u> | <u>\$ 1,428</u> | <u>\$ 2,772</u> | <u>\$ 4,559</u> |

| (in thousands) | Lease/Contract Terminations | | | |
|-------------------------------|-----------------------------|-------------|--------------|---------------|
| | 2012 and Prior Plans | 2013 Plans | 2014 Plans | Total |
| | | | | |
| Balance at December 31, 2013 | \$ 748 | \$ 98 | \$ — | \$ 846 |
| Provisions | 11 | 80 | 33 | 124 |
| Amounts applied | (100) | (266) | — | (366) |
| Change in estimate | (92) | 95 | — | 3 |
| Balance at September 30, 2014 | <u>\$ 567</u> | <u>\$ 7</u> | <u>\$ 33</u> | <u>\$ 607</u> |

Other Restructuring Costs

| (in thousands) | 2012 and Prior Plans | 2013 Plans | 2014 Plans | Total |
|-------------------------------|-------------------------|------------|------------|----------|
| Balance at December 31, 2013 | \$ 58 | \$ 658 | \$ — | \$ 716 |
| Provisions | — | 17 | 2,237 | 2,254 |
| Amounts applied | (61) | (389) | (1,251) | (1,701) |
| Change in estimate | 28 | (274) | — | (246) |
| Balance at September 30, 2014 | \$ 25 | \$ 12 | \$ 986 | \$ 1,023 |

The following table provides the year-to-date changes in the restructuring accruals by segment:

| (in thousands) | December 31, 2013 | Provisions | Amounts Applied | Change in Estimates | September 30, 2014 |
|---|----------------------|------------|--------------------|------------------------|-----------------------|
| Dental Consumable and Certain International Businesses | \$ 656 | \$ 1,885 | \$ (386) | \$ (141) | \$ 2,014 |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | 6,333 | 3,613 | (5,325) | (1,275) | 3,346 |
| Healthcare and Emerging Markets Businesses | 1,245 | 689 | (1,001) | (104) | 829 |
| All Other | 374 | 293 | (602) | (65) | — |
| Total | \$ 8,608 | \$ 6,480 | \$ (7,314) | \$ (1,585) | \$ 6,189 |

NOTE 10 – FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company's activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates, interest rates and commodity prices. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company's operating results and equity. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert variable rate debt to fixed rate debt and to convert fixed rate debt to variable rate debt, cross currency basis swaps to convert debt denominated in one currency to another currency and commodity swaps to fix certain variable raw material costs.

Derivative Instruments Designated as Hedging

Cash Flow Hedges

The following table summarizes the notional amounts of cash flow hedges by derivative instrument type at September 30, 2014 and the notional amounts expected to mature during the next 12 months, with a discussion of the various cash flow hedges by derivative instrument type following the table:

| (in thousands) | Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months |
|---|---------------------------|---|
| Foreign exchange forward contracts | \$ 371,154 | \$ 278,247 |
| Interest rate swaps | 182,496 | — |
| Commodity contracts | 1,949 | 1,949 |
| Total derivative instruments designated as cash flow hedges | \$ 555,599 | \$ 280,196 |

Foreign Exchange Risk Management

The Company uses a layered hedging program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings of the consolidated Company. The Company accounts for the designated foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the tested effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded on the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time value component of the fair value of the derivative is deemed ineffective and is reported currently in "Other expense (income), net" on the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operating activities on the Consolidated Statements of Cash Flows. The Company hedges various currencies, with the most significant activity occurring in euros, Swedish kronor, Canadian dollars, and Swiss francs.

These foreign exchange forward contracts generally have maturities up to 18 months and the counterparties to the transactions are typically large international financial institutions.

Interest Rate Risk Management

The Company uses interest rate swaps to convert a portion of its variable interest rate debt to fixed interest rate debt. At September 30, 2014, the Company has two groups of significant interest rate swaps. On September 29, 2014, the Company replaced the maturing 12.6 billion Japanese yen variable interest rate debt facility with a new variable rate facility for the same amount. In addition, the Company settled existing swaps that converted the underlying variable interest rate on the matured facility and issued new interest rate swaps with notional amounts totaling 12.6 billion Japanese yen, which effectively converts the underlying variable interest rate on the new facility to a fixed interest rate of 0.9% for a term of five years ending September 2019. Another swap has a notional amount of 65.0 million Swiss francs, and effectively converts the underlying variable interest rate of a Swiss franc denominated loan to a fixed interest rate of 0.7% for an initial term of five years, ending in September 2016.

The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in cash from operating activities on the Consolidated Statements of Cash Flows.

Commodity Risk Management

The Company enters into precious metal commodity swap contracts to effectively fix certain variable raw material costs typically for up to 18 months. These swaps are used to stabilize the cost of components used in the production of certain of the Company's products. The Company generally accounts for the commodity swaps as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the tested effectiveness of the commodity swaps. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded on the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time value component of the fair value of the derivative is deemed ineffective and is reported currently in "Interest expense" on the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operating activities on the Consolidated Statements of Cash Flows.

The following tables summarize the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and income (expense) in the Company's Consolidated Statements of Operations related to all cash flow hedges for the three months ended September 30, 2014 and 2013:

September 30, 2014

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Effective Portion Reclassified from AOCI into Income (Expense) | Ineffective Portion Recognized in Income (Expense) |
|------------------------------------|------------------------|---|--|--|
| Effective Portion: | | | | |
| Interest rate swaps | \$ 332 | Interest expense | \$ (929) | |
| Foreign exchange forward contracts | 7,440 | Cost of products sold | (2,191) | |
| Foreign exchange forward contracts | 322 | SG&A expenses | (16) | |
| Commodity contracts | (311) | Cost of products sold | (95) | |
| Ineffective Portion: | | | | |
| Foreign exchange forward contracts | | Other expense (income), net | | \$ (146) |
| Total in cash flow hedging | <u>\$ 7,783</u> | | <u>\$ (3,231)</u> | <u>\$ (146)</u> |

September 30, 2013

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Effective Portion Reclassified from AOCI into Income (Expense) | Ineffective Portion Recognized in Income (Expense) |
|------------------------------------|------------------------|---|--|--|
| Effective Portion: | | | | |
| Interest rate swaps | \$ (414) | Interest expense | \$ (924) | |
| Foreign exchange forward contracts | (2,488) | Cost of products sold | 460 | |
| Foreign exchange forward contracts | (273) | SG&A expenses | (27) | |
| Commodity contracts | 457 | Cost of products sold | (190) | |
| Ineffective Portion: | | | | |
| Foreign exchange forward contracts | | Other expense (income), net | | \$ 134 |
| Commodity contracts | | Interest expense | | (13) |
| Total for cash flow hedging | \$ (2,718) | | \$ (681) | \$ 121 |

The following tables summarize the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and income (expense) in the Company's Consolidated Statements of Operations related to all cash flow hedges for the nine months ended September 30, 2014 and 2013:

September 30, 2014

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Effective Portion Reclassified from AOCI into Income (Expense) | Ineffective Portion Recognized in Income (Expense) |
|------------------------------------|------------------------|---|--|--|
| Effective Portion: | | | | |
| Interest rate swaps | \$ (205) | Interest expense | \$ (2,785) | |
| Foreign exchange forward contracts | 3,871 | Cost of products sold | (5,487) | |
| Foreign exchange forward contracts | 357 | SG&A expenses | (174) | |
| Commodity contracts | (108) | Cost of products sold | (498) | |
| Ineffective Portion: | | | | |
| Foreign exchange forward contracts | | Other expense (income), net | | \$ (191) |
| Commodity contracts | | Interest expense | | (24) |
| Total in cash flow hedging | \$ 3,915 | | \$ (8,944) | \$ (215) |

September 30, 2013

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Effective Portion Reclassified from AOCI into Income (Expense) | Ineffective Portion Recognized in Income (Expense) |
|------------------------------------|------------------------|---|--|--|
| Effective Portion: | | | | |
| Interest rate swaps | \$ 180 | Interest expense | \$ (2,755) | |
| Foreign exchange forward contracts | (3,790) | Cost of products sold | 1,589 | |
| Foreign exchange forward contracts | (184) | SG&A expenses | (67) | |
| Commodity contracts | (802) | Cost of products sold | 12 | |
| Ineffective Portion: | | | | |
| Foreign exchange forward contracts | | Other expense (income), net | | \$ 323 |
| Commodity contracts | | Interest expense | | (54) |
| Total for cash flow hedging | \$ (4,596) | | \$ (1,221) | \$ 269 |

Overall, the derivatives designated as cash flow hedges are considered to be highly effective. At September 30, 2014, the Company expects to reclassify \$1.6 million of deferred net losses on cash flow hedges recorded in AOCI to the Consolidated Statements of Operations during the next 12 months. This reclassification is primarily due to the sale of inventory that includes hedged purchases and recognized interest expense on interest rate swaps. The term over which the Company is hedging exposures to variability of cash flows (for all forecasted transactions, excluding interest payments on variable interest rate debt) is typically 18 months.

For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 3, Comprehensive Income.

Hedges of Net Investments in Foreign Operations

The Company has significant investments in foreign subsidiaries the most significant of which are denominated in euros, Swiss francs, Japanese yen and Swedish kronor. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. To hedge a portion of this exposure the Company employs both derivative and non-derivative financial instruments. The derivative instruments consist of foreign exchange forward contracts and cross currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in derivative and non-derivative financial instruments designated as hedges of net investments, which are included in AOCI. Any cash flows associated with these instruments are included in investing activities on the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, in which case all cash flows will be classified as financing activities on the Consolidated Statements of Cash Flows.

The following table summarizes the notional amounts of hedges of net investments by derivative instrument type at September 30, 2014 and the notional amounts expected to mature during the next 12 months:

| (in thousands) | Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months |
|--|---------------------------------|---|
| Foreign exchange forward contracts | \$ 435,730 | \$ 247,543 |
| Total derivative instruments designated as net investment hedges | <u>\$ 435,730</u> | <u>\$ 247,543</u> |

On February 14, 2014, the Company de-designated 449.8 million euros of foreign exchange forward contracts that were previously designated as net investment hedges. The change in the value of the de-designated hedges will be recorded in "Other expense (income), net" on the Consolidated Statements of Operations and will offset the change in the value of non-designated

euro denominated cross currency basis swaps as further noted in the section below titled Derivative Instruments Not Designated as Hedges.

On September 4, 2014, the Company settled and replaced with new contracts net investment hedges totaling 432.5 million Swiss francs. The settled hedge instruments were cross currency basis swaps that matured periodically through April 2018. The Company replaced these hedges with new foreign exchange forwards contracts, totaling 258.1 million Swiss francs, which have layered maturity dates from December 2014 through September 2016. These settled net investment hedges resulted in cash receipts totaling \$0.1 million during September 2014.

The fair value of the cross currency basis swaps and foreign exchange forward contracts is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross currency swap basis rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

The following tables summarize the amount of gains (losses) recorded in AOCI on the Consolidated Balance Sheets and income (expense) on the Company's Consolidated Statements of Operations related to the hedges of net investments for the three months ended September 30, 2014 and 2013:

September 30, 2014

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Recognized in Income (Expense) |
|------------------------------------|------------------------|---|-----------------------------------|
| Effective Portion: | | | |
| Cross currency basis swaps | \$ 22,427 | Interest income | \$ 501 |
| | | Interest expense | (1,726) |
| Foreign exchange forward contracts | 21,167 | Other expense (income), net | 569 |
| Total for net investment hedging | <u>\$ 43,594</u> | | <u>\$ (656)</u> |

September 30, 2013

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Recognized in Income (Expense) |
|----------------------------------|------------------------|---|-----------------------------------|
| Effective Portion: | | | |
| Cross currency basis swaps | \$ (49,614) | Interest income | \$ 1,331 |
| | | Interest expense | 755 |
| Total for net investment hedging | <u>\$ (49,614)</u> | | <u>\$ 2,086</u> |

The following tables summarize the amount of gains (losses) recorded in AOCI on the Consolidated Balance Sheets and income (expense) on the Company's Consolidated Statements of Operations related to the hedges of net investments for the nine months ended September 30, 2014 and 2013:

September 30, 2014

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Recognized in Income (Expense) |
|------------------------------------|------------------------|---|-----------------------------------|
| Effective Portion: | | | |
| Cross currency basis swaps | \$ 19,340 | Interest income | \$ 1,852 |
| | | Interest expense | (1,569) |
| Foreign exchange forward contracts | 25,508 | Other expense (income), net | 743 |
| Total for net investment hedging | <u>\$ 44,848</u> | | <u>\$ 1,026</u> |

September 30, 2013

| (in thousands) | Gain (Loss) in AOCI | Consolidated Statements of Operations Location | Recognized in Income (Expense) |
|----------------------------------|------------------------|---|-----------------------------------|
| Effective Portion: | | | |
| Cross currency basis swaps | \$ (23,464) | Interest income | \$ 3,988 |
| | | Interest expense | 497 |
| Total for net investment hedging | <u>\$ (23,464)</u> | | <u>\$ 4,485</u> |

Fair Value Hedges

The Company uses interest rate swaps to convert a portion of its fixed interest rate debt to variable interest rate debt. The Company has a group of U.S. dollar denominated interest rate swaps with an initial total notional value of \$150.0 million to effectively convert the underlying fixed interest rate of 4.1% on the Company's \$250.0 million Private Placement Notes ("PPN") to variable rate for an initial term of five years, ending February 2016. The notional value of the swaps will decline proportionately as portions of the PPN mature. These interest rate swaps are designated as fair value hedges of the interest rate risk associated with the hedged portion of the fixed rate PPN. Accordingly, the Company will carry the portion of the hedged debt at fair value, with the change in debt and swaps offsetting each other on the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities on the Consolidated Statements of Cash Flows.

The following table summarizes the notional amounts of fair value hedges by derivative instrument type at September 30, 2014 and the notional amounts expected to mature during the next 12 months:

| (in thousands) | Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months |
|---------------------|---------------------------------|---|
| Interest rate swaps | \$ 105,000 | \$ 60,000 |

The following tables summarize the amount of income (expense) recorded on the Company's Consolidated Statements of Operations related to the hedges of fair value for the three and nine months ended September 30, 2014 and 2013:

| (in thousands) | Consolidated Statements of Operations Location | Income (Expense) Recognized | | | |
|---------------------|--|--|-----------------------|---|-----------------------|
| | | Three Months Ended September 30, 2014 | September 30, 2013 | Nine Months Ended September 30, 2014 | September 30, 2013 |
| Interest rate swaps | Interest expense | \$ (107) | \$ 251 | \$ 113 | \$ 163 |

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in "Other expense (income), net" on the Consolidated Statements of Operations. The Company primarily uses foreign exchange forward contracts and cross currency basis swaps to hedge these risks. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in cash from operating activities on the Consolidated Statements of Cash Flows. Any cash flows associated with the cross currency basis swaps not designated as hedges are included in investing activities on the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, in which case the cash flows will be classified as financing activities on the Consolidated Statements of Cash Flows.

The following tables summarize the aggregate notional amounts of the Company's economic hedges not designated as hedges by derivative instrument types at September 30, 2014 and the notional amounts expected to mature during the next 12 months:

| (in thousands) | Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months |
|--|---------------------------|---|
| Foreign exchange forward contracts | \$ 1,075,094 | \$ 1,075,094 |
| Interest rate swaps | 3,192 | 912 |
| Cross currency basis swaps | 637,528 | 637,528 |
| Total for instruments not designated as hedges | <u>\$ 1,715,814</u> | <u>\$ 1,713,534</u> |

The Company maintains Swiss franc denominated cross currency basis swaps to offset an intercompany Swiss franc note receivable at a U.S. dollar functional entity. The hedge declines each quarter to coincide with expected repayments of the note. At September 30, 2014, the remaining notional value of the cross currency swaps was 66.4 million Swiss francs.

On February 14, 2014, a series of U.S. dollar denominated intercompany note receivables were transferred from a euro functional entity to a U.S. dollar functional entity at which point the underlying foreign currency revaluation risk that was hedged by non-designated cross currency swaps totaling 449.8 million euro was eliminated. As a result, the company de-designated an offsetting amount of 449.8 million euro of net investment hedges. The change in the value of the de-designated net investment hedges will be recorded in "Other expense (income), net" on the Consolidated Statements of Operations and will offset the change in the value of the non-designated euro denominated cross currency swaps until both sets of hedges mature in December 2014.

The following table summarizes the amounts of gains (losses) recorded on the Company's Consolidated Statements of Operations related to the economic hedges not designated as hedging for the three and nine months ended September 30, 2014 and 2013:

| (in thousands) | Consolidated Statements of Operations Location | Gain (Loss) Recognized | |
|--|--|---------------------------------------|------------------|
| | | Three Months Ended September 30, 2014 | 2013 |
| Foreign exchange forward contracts (a) | Other expense (income), net | \$ 36,759 | \$ 3,110 |
| DIO equity option contracts | Other expense (income), net | (34) | 8 |
| Interest rate swaps | Interest expense | (20) | (7) |
| Cross currency basis swaps (a) | Other expense (income), net | (40,596) | 10,625 |
| Total for instruments not designated as hedges | | <u>\$ (3,891)</u> | <u>\$ 13,736</u> |

(a) The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances which are recorded in "Other expense (income), net" on the Consolidated Statements of Operations.

| (in thousands) | Consolidated Statements of Operations Location | Gain (Loss) Recognized | |
|--|--|--------------------------------------|------------------|
| | | Nine Months Ended September 30, 2014 | 2013 |
| Foreign exchange forward contracts (b) | Other expense (income), net | \$ 31,635 | \$ 6,193 |
| DIO equity option contracts | Other expense (income), net | (169) | 20 |
| Interest rate swaps | Interest expense | (47) | 14 |
| Cross currency basis swaps (b) | Other expense (income), net | (43,776) | 9,250 |
| Total for instruments not designated as hedges | | <u>\$ (12,357)</u> | <u>\$ 15,477</u> |

(b) The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances which are recorded in "Other expense (income), net" on the Consolidated Statements of Operations.

Consolidated Balance Sheets Location of Derivative Fair Values

The following tables summarize the fair value and consolidated balance sheet location of the Company's derivatives at September 30, 2014 and December 31, 2013:

| | | September 30, 2014 | | | |
|--------------------------|------------------------------------|--|------------------------------|---------------------|------------------------------|
| (in thousands) | Designated as Hedges | Prepaid Expenses and Other Current Assets, Net | Other Noncurrent Assets, Net | Accrued Liabilities | Other Noncurrent Liabilities |
| | Foreign exchange forward contracts | \$ 17,622 | \$ 7,929 | \$ 2,055 | \$ 288 |
| | Commodity contracts | — | — | 258 | — |
| | Interest rate swaps | 1,277 | 445 | 587 | 689 |
| | Total | \$ 18,899 | \$ 8,374 | \$ 2,900 | \$ 977 |
| Not Designated as Hedges | | | | | |
| | Foreign exchange forward contracts | \$ 50,435 | \$ — | \$ 5,020 | \$ — |
| | DIO equity option contracts | — | — | — | 289 |
| | Interest rate swaps | — | — | 75 | 170 |
| | Cross currency basis swaps | 1,622 | — | 81,995 | — |
| | Total | \$ 52,057 | \$ — | \$ 87,090 | \$ 459 |
| | | December 31, 2013 | | | |
| (in thousands) | Designated as Hedges | Prepaid Expenses and Other Current Assets, Net | Other Noncurrent Assets, Net | Accrued Liabilities | Other Noncurrent Liabilities |
| | Foreign exchange forward contracts | \$ 1,517 | \$ 255 | \$ 10,280 | \$ 940 |
| | Commodity contracts | — | 1 | 434 | 1 |
| | Interest rate swaps | 789 | 1,617 | 466 | 419 |
| | Cross currency basis swaps | 530 | — | 2,223 | 16,413 |
| | Total | \$ 2,836 | \$ 1,873 | \$ 13,403 | \$ 17,773 |
| Not Designated as Hedges | | | | | |
| | Foreign exchange forward contracts | \$ 3,128 | \$ — | \$ 2,328 | \$ — |
| | DIO equity option contracts | — | — | — | 142 |
| | Interest rate swaps | — | — | 85 | 256 |
| | Cross currency basis swaps | — | — | 38,551 | 1,941 |
| | Total | \$ 3,128 | \$ — | \$ 40,964 | \$ 2,339 |

Balance Sheet Offsetting

Substantially all of the Company's derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis on the Consolidated Balance Sheets.

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2014:

| (in thousands) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | | Net Amount |
|------------------------------------|-----------------------------|---|---|--|-------------------------------------|------------------|
| | | | | Financial Instruments | Cash Collateral Received/Pledged | |
| Assets | | | | | | |
| Foreign exchange forward contracts | \$ 75,986 | \$ — | \$ 75,986 | \$ (15,258) | \$ — | \$ 60,728 |
| Interest rate swaps | 1,722 | — | 1,722 | (780) | — | 942 |
| Cross currency basis swaps | 1,622 | — | 1,622 | (926) | — | 696 |
| Total Assets | \$ 79,330 | \$ — | \$ 79,330 | \$ (16,964) | \$ — | \$ 62,366 |

| (in thousands) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | | Net Amount |
|------------------------------------|-----------------------------|---|---|--|-------------------------------------|------------------|
| | | | | Financial Instruments | Cash Collateral Received/Pledged | |
| Liabilities | | | | | | |
| Foreign exchange forward contracts | \$ 7,362 | \$ — | \$ 7,362 | \$ (4,791) | \$ — | \$ 2,571 |
| Commodity contracts | 258 | — | 258 | — | — | 258 |
| DIO equity option contracts | 289 | — | 289 | — | — | 289 |
| Interest rate swaps | 1,522 | — | 1,522 | (1,170) | — | 352 |
| Cross currency basis swaps | 81,995 | — | 81,995 | (11,003) | — | 70,992 |
| Total Liabilities | \$ 91,426 | \$ — | \$ 91,426 | \$ (16,964) | \$ — | \$ 74,462 |

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2013:

| (in thousands) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | | Net Amount |
|------------------------------------|-----------------------------|---|---|--|-------------------------------------|---------------|
| | | | | Financial Instruments | Cash Collateral Received/Pledged | |
| Assets | | | | | | |
| Foreign exchange forward contracts | \$ 4,900 | \$ — | \$ 4,900 | \$ (4,641) | \$ — | \$ 259 |
| Commodity contracts | 1 | — | 1 | (1) | — | — |
| Interest rate swaps | 2,406 | — | 2,406 | (1,979) | — | 427 |
| Cross currency basis swaps | 530 | — | 530 | (530) | — | — |
| Total Assets | \$ 7,837 | \$ — | \$ 7,837 | \$ (7,151) | \$ — | \$ 686 |

| (in thousands) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | | Net Amount |
|------------------------------------|-----------------------------|---|---|--|-------------------------------------|------------------|
| | | | | Financial Instruments | Cash Collateral Received/Pledged | |
| Liabilities | | | | | | |
| Foreign exchange forward contracts | \$ 13,548 | \$ — | \$ 13,548 | \$ (3,467) | \$ — | \$ 10,081 |
| Commodity contracts | 435 | — | 435 | (1) | — | 434 |
| DIO equity option contracts | 142 | — | 142 | — | — | 142 |
| Interest rate swaps | 1,226 | — | 1,226 | (62) | — | 1,164 |
| Cross currency basis swaps | 59,128 | — | 59,128 | (3,621) | — | 55,507 |
| Total Liabilities | \$ 74,479 | \$ — | \$ 74,479 | \$ (7,151) | \$ — | \$ 67,328 |

NOTE 11 – FAIR VALUE MEASUREMENT

The Company records financial instruments at fair value with unrealized gains and losses related to certain financial instruments reflected in AOCI on the Consolidated Balance Sheets. In addition, the Company recognizes certain liabilities at fair value. The Company applies the market approach for recurring fair value measurements. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value of financial instruments is determined by reference to various market data and other valuation techniques as appropriate. The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments. The Company estimated the fair value and carrying value of total long-term debt, including the current portion, was \$1,314.5 million and \$1,275.7 million, respectively, at September 30, 2014. At December 31, 2013, the Company estimated the fair value and carrying value, including the current portion, was \$1,387.7 million and \$1,370.8 million, respectively. The interest rate on the \$450.0 million Senior Notes, the \$300.0 million Senior Notes, and the \$250.0 million PPN are fixed rates of 4.2%, 2.8% and 4.1%, respectively, and their fair value is

based on the interest rates as of September 30, 2014. The interest rates on variable rate term loan debt and commercial paper are consistent with current market conditions, therefore the fair value of these instruments approximates their carrying values.

The following tables set forth by level within the fair value hierarchy the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis at September 30, 2014 and December 31, 2013, which are classified as "Cash and cash equivalents," "Prepaid expenses and other current assets, net," "Other noncurrent assets, net," "Accrued liabilities," and "Other noncurrent liabilities" in the Consolidated Balance Sheets. Financial assets and liabilities that are recorded at fair value as of the balance sheet date are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

| (in thousands) | September 30, 2014 | | | |
|------------------------------------|--------------------|-------------|-------------------|------------------|
| | Total | Level 1 | Level 2 | Level 3 |
| Assets | | | | |
| Interest rate swaps | \$ 1,722 | \$ — | \$ 1,722 | \$ — |
| Cross currency basis swaps | 1,622 | — | 1,622 | — |
| Foreign exchange forward contracts | 75,986 | — | 75,986 | — |
| DIO Corporation convertible bonds | 65,453 | — | — | 65,453 |
| Total assets | \$ 144,783 | \$ — | \$ 79,330 | \$ 65,453 |
| Liabilities | | | | |
| Interest rate swaps | \$ 1,521 | \$ — | \$ 1,521 | \$ — |
| Commodity contracts | 258 | — | 258 | — |
| Cross currency basis swaps | 81,995 | — | 81,995 | — |
| Foreign exchange forward contracts | 7,363 | — | 7,363 | — |
| Long term debt | 106,023 | — | 106,023 | — |
| DIO equity option contracts | 289 | — | — | 289 |
| Total liabilities | \$ 197,449 | \$ — | \$ 197,160 | \$ 289 |

| (in thousands) | December 31, 2013 | | | |
|------------------------------------|-------------------|-------------|-------------------|------------------|
| | Total | Level 1 | Level 2 | Level 3 |
| Assets | | | | |
| Interest rate swaps | \$ 2,406 | \$ — | \$ 2,406 | \$ — |
| Commodity contracts | 1 | — | 1 | — |
| Cross currency basis swaps | 530 | — | 530 | — |
| Foreign exchange forward contracts | 4,900 | — | 4,900 | — |
| DIO Corporation convertible bonds | 70,019 | — | — | 70,019 |
| Total assets | \$ 77,856 | \$ — | \$ 7,837 | \$ 70,019 |
| Liabilities | | | | |
| Interest rate swaps | \$ 1,226 | \$ — | \$ 1,226 | \$ — |
| Commodity contracts | 435 | — | 435 | — |
| Cross currency basis swaps | 59,128 | — | 59,128 | — |
| Foreign exchange forward contracts | 13,548 | — | 13,548 | — |
| Long term debt | 152,370 | — | 152,370 | — |
| DIO equity option contracts | 142 | — | — | 142 |
| Total liabilities | \$ 226,849 | \$ — | \$ 226,707 | \$ 142 |

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, future commodities prices and credit risks. As discussed in Note 10, Financial Instruments and Derivatives, commodity

contracts, certain interest rate swaps and foreign exchange forward contracts are considered cash flow hedges. In addition, certain cross currency basis swaps and foreign exchange forward contracts are considered hedges of net investments in foreign operations.

The Company uses the income method valuation technique to estimate the fair value of the DIO Corporation convertible bonds. The significant unobservable inputs for valuing the corporate bonds are DIO Corporation's stock volatility factor of approximately 40% and corporate bond rating which implies approximately a 9.3% discount rate on the valuation model. Significant observable inputs used to value the corporate bonds include foreign exchange rates and DIO Corporation's period-ending market stock price.

The Company has valued the DIO equity option contracts using a Monte Carlo simulation which uses several estimates and probability assumptions by management including the future stock price, the stock price as a multiple of DIO earnings and the probability of the sellers to reduce their shares held by selling into the open market. The fair value of equity option contracts are reported in "Other noncurrent liabilities," on the Consolidated Balance Sheets and changes in the fair value are reported in "Other expense (income), net" in the Consolidated Statements of Operations.

The following table presents a rollforward of the Company's Level 3 holdings measured at fair value on a recurring basis using unobservable inputs:

| (in thousands) | DIO Corporation Convertible Bonds | DIO Equity Options Contracts |
|---|---|------------------------------------|
| Balance at December 31, 2013 | \$ 70,019 | \$ (142) |
| Unrealized gain: | | |
| Reported in AOCI, pretax | 1,246 | — |
| Unrealized loss: | | |
| Reported in other expense (income), net | — | (169) |
| Effects of exchange rate changes | (5,812) | 22 |
| Balance at September 30, 2014 | <u>\$ 65,453</u> | <u>\$ (289)</u> |

For the nine months ended September 30, 2014, there were no purchases, issuances or transfers of Level 3 financial instruments.

NOTE 12 – INCOME TAXES

Uncertainties in Income Taxes

The Company recognizes in the interim consolidated financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date of the Company's interim consolidated financial statements. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately \$23.6 million. Of this total, approximately \$7.0 million represents the amount of unrecognized tax benefits that, if recognized would affect the effective income tax rate. In addition, expiration of statutes of limitation in various jurisdictions during the next 12 months could include unrecognized tax benefits of approximately \$0.3 million.

Other Tax Matters

For the nine months ended September 30, 2014, the effective tax rate was unfavorably impacted by the Company's change in the mix of consolidated earnings. For the nine months ended September 30, 2013, the Company recorded a tax benefit of \$9.4 million related to U.S. federal legislative changes enacted in January 2013, relating to 2012, and \$9.3 million of benefits related to prior year tax matters.

NOTE 13 – FINANCING ARRANGEMENTS

The Company refinanced the first required payment of \$75.0 million under the PPN due February 2016 by issuing commercial paper. The second required payment of \$100.0 million due in February 2015 has been classified as current on the Consolidated Balance Sheets.

The Company repaid the first annual principal amortization of \$8.8 million representing a 5% mandatory principal amortization due in each of the first six years under the terms of the PNC Term Loan with a final maturity of August 26, 2020. The second annual installment in the amount of \$8.8 million will be due in August 2015 and has been classified as current on the Consolidated Balance Sheets.

On July 23, 2014, the Company entered into an Amended and Extended Revolving Credit Agreement to replace the 2011 Revolving Credit Agreement dated July 27, 2011, that had provided for a multi-currency revolving credit facility in an aggregate amount of up to \$500.0 million through July 27, 2016. The new Credit Agreement provides for a new five year, \$500.0 million multi-currency revolving credit facility through July 23, 2019 (the "Facility") to provide working capital from time to time for the Company and for other general corporate purposes. The Facility is unsecured and contains certain affirmative and negative covenants, which are generally consistent with the prior agreement, relating to the Company's operations and financial condition, including prescribed leverage and interest coverage ratios. The Facility contains customary events of default. Upon the occurrence of an event of default, all outstanding borrowings under the Credit Agreement may be accelerated and become immediately due and payable. At September 30, 2014, there were no outstanding borrowings, in the form of issued commercial paper, under the current multi-currency revolving facility.

On September 29, 2014, the Company entered into a new Samurai Loan Agreement to replace the maturing Samurai Loan Agreement dated August 27, 2011, in an aggregate amount of 12.6 billion Japanese yen. The new Samurai Loan Agreement ("Samurai Loan") provides for a new five-year, 12.6 billion Japanese yen term loan through September 30, 2019. The Samurai Loan is designated as a net investment hedge. The Samurai Loan is unsecured and contains certain affirmative and negative covenants relating to the Company's operations and financial condition, including prescribed leverage and interest coverage ratios. The Samurai Loan contains customary events of default. Upon the occurrence of an event of default, all outstanding borrowings under the Samurai Loan may be accelerated and become immediately due and payable.

The Company's revolving credit facility, term loans and PPN contain certain affirmative and negative covenants relating to the Company's operations and financial condition. At September 30, 2014, the Company was in compliance with all debt covenants.

At September 30, 2014, the Company had total unused lines of credit, including lines available under its short-term arrangements and revolving credit agreement, of \$567.7 million.

NOTE 14 – GOODWILL AND INTANGIBLE ASSETS

The Company performed the required annual impairment tests of goodwill as of April 30, 2014 on 15 reporting units. As discussed in Note 6, Segment Information, effective in the first quarter of 2014, the Company realigned reporting responsibilities for multiple locations. For any realignment that resulted in reporting unit changes, the Company applied the relative fair value method to determine the reallocation of goodwill of the associated reporting units.

To determine the fair value of the Company's reporting units, the Company uses a discounted cash flow model with market-based support as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five-year forecasted cash flows plus a terminal value based on a multiple of earnings. In addition, the Company applies gross margin and operating expense assumptions consistent with historical trends. The total cash flows were discounted based on a range between 8.6% to 14.0%, which included assumptions regarding the Company's weighted-average cost of capital. The Company considered the current market conditions both in the U.S. and globally, when determining its assumptions. Lastly, the Company reconciled the aggregated fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions. As a result of the annual impairment tests of goodwill, no impairment was identified.

In addition, the Company assessed the annual impairment of indefinite-lived intangible assets as of April 30, 2014, which largely consists of acquired tradenames, in conjunction with the annual impairment tests of goodwill. The performance of the Company's annual impairment test did not result in any impairment of the Company's indefinite-lived assets.

A reconciliation of changes in the Company's goodwill is as follows:

| (in thousands) | Dental Consumable Businesses and Certain International Businesses | Dental Specialty and Laboratory Businesses and Certain Global Distribution Businesses | Healthcare and Emerging Markets Businesses | Total |
|--|---|--|--|---------------------|
| Balance at December 31, 2013 | \$ 325,044 | \$ 1,576,126 | \$ 380,426 | \$ 2,281,596 |
| Adjustments of provisional amounts on prior acquisitions | — | (240) | — | (240) |
| Effects of exchange rate changes | (4,784) | (100,804) | (15,072) | (120,660) |
| Balance at September 30, 2014 | <u>\$ 320,260</u> | <u>\$ 1,475,082</u> | <u>\$ 365,354</u> | <u>\$ 2,160,696</u> |

Identifiable definite-lived and indefinite-lived intangible assets consist of the following:

| (in thousands) | September 30, 2014 | | | December 31, 2013 | | |
|--|-----------------------------|-----------------------------|---------------------------|-----------------------------|-----------------------------|---------------------------|
| | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount |
| Patents | \$ 178,007 | \$ (95,318) | \$ 82,689 | \$ 181,847 | \$ (91,736) | \$ 90,111 |
| Trademarks | 79,120 | (37,372) | 41,748 | 85,922 | (35,994) | 49,928 |
| Licensing agreements | 31,507 | (22,343) | 9,164 | 31,950 | (20,992) | 10,958 |
| Customer relationships | 470,955 | (101,122) | 369,833 | 497,108 | (82,381) | 414,727 |
| Total definite-lived | <u>\$ 759,589</u> | <u>\$ (256,155)</u> | <u>\$ 503,434</u> | <u>\$ 796,827</u> | <u>\$ (231,103)</u> | <u>\$ 565,724</u> |
| Indefinite-lived Trademarks and In-process R&D | \$ 206,678 | \$ — | \$ 206,678 | \$ 229,599 | \$ — | \$ 229,599 |
| Total identifiable intangible assets | <u>\$ 966,267</u> | <u>\$ (256,155)</u> | <u>\$ 710,112</u> | <u>\$ 1,026,426</u> | <u>\$ (231,103)</u> | <u>\$ 795,323</u> |

NOTE 15 – COMMITMENTS AND CONTINGENCIES

Litigation

On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a class action suit in San Francisco County, California alleging that the Company misrepresented that its Cavitron® ultrasonic scalers are suitable for use in oral surgical procedures. The Complaint seeks a recall of the product and refund of its purchase price to dentists who have purchased it for use in oral surgery. The Court certified the case as a class action in June 2006 with respect to the breach of warranty and unfair business practices claims. The class that was certified is defined as California dental professionals who, at any time during the period beginning June 18, 2000 through September 14, 2012, purchased and used one or more Cavitron® ultrasonic scalers for the performance of oral surgical procedures on their patients, which Cavitrons® were accompanied by Directions for Use that "Indicated" Cavitron® use for "periodontal debridement for all types of periodontal disease." The case went to trial in September 2013, and on January 22, 2014, the San Francisco Superior Court issued its decision in the Company's favor, rejecting all of the plaintiffs' claims. The plaintiffs have appealed the Superior Court's decision, and the appeal is now pending. The Company intends to defend against this appeal.

On December 12, 2006, a Complaint was filed by Carole Hildebrand, DDS and Robert Jaffin, DDS in the Eastern District of Pennsylvania (the Plaintiffs subsequently added Dr. Mitchell Goldman as a named class representative). The case was filed by the same law firm that filed the Weinstat case in California. The Complaint asserts putative class action claims on behalf of dentists located in New Jersey and Pennsylvania. The Complaint seeks damages and asserts that the Company's Cavitron® ultrasonic scaler was negligently designed and sold in breach of contract and warranty arising from misrepresentations about the potential uses of the product because it cannot assure the delivery of potable or sterile water. Following grant of a Company Motion and dismissal of the case for lack of jurisdiction, the plaintiffs filed a second complaint under the name of Dr. Hildebrand's corporate practice, Center City Periodontists, asserting the same allegations (this case is now proceeding under the name "Center City

Periodontists”). The plaintiffs moved to have the case certified as a class action, to which the Company has objected and filed its brief. The Court has not yet ruled on class certification. The Court subsequently granted a Motion filed by the Company and dismissed plaintiffs’ New Jersey Consumer Fraud and negligent design claims, leaving only a breach of express warranty claim, in response to which the Company has filed a Motion for Summary Judgment.

On January 20, 2014, the Company was served with a *qui tam* complaint filed by two former and one current employee of the Company under the Federal False Claims Act and equivalent state and city laws. The lawsuit was previously under seal in the U.S. District Court for the Eastern District of Pennsylvania. The complaint alleges, among other things, that the Company engaged in various illegal marketing activities, and thereby caused dental and other healthcare professionals to file false claims for reimbursement with Federal and State governments. The relators seek injunctive relief, fines, treble damages, and attorneys’ fees and costs. On January 27, 2014, the United States filed with the Court a notice that it had elected not to intervene in the *qui tam* action at this time. The United States’ notice indicated that the named state and city co-plaintiffs had authorized the United States to communicate to the Court that they also had decided not to intervene at this time. These non-intervention decisions do not prevent the *qui tam* relators from litigating this action, and the United States and/or the named states and/or cities may seek to intervene in the action at a later time. On September 4, 2014, the Company’s motion to dismiss the complaint was granted in part and denied in part. The Company intends to vigorously defend itself in the litigation.

The Company does not believe a loss is probable related to the above litigation. Further a reasonable estimate of a possible range of loss cannot be made. In the event that one or more of these matters is unfavorably resolved, it is possible the Company’s results from operations could be materially impacted.

In 2012, the Company received subpoenas from the United States Attorney’s Office for the Southern District of Indiana (the “USAO”) and from the Office of Foreign Assets Control of the United States Department of the Treasury (“OFAC”) requesting documents and information related to compliance with export controls and economic sanctions regulations by certain of its subsidiaries. The Company has voluntarily contacted OFAC and the Bureau of Industry and Security of the United States Department of Commerce (“BIS”), in connection with these matters as well as regarding compliance with export controls and economic sanctions regulations by certain other business units of the Company identified in connection with an internal review by the Company. The Company is cooperating with the USAO, OFAC and BIS with respect to these matters.

At this stage of the inquiries, the Company is unable to predict the ultimate outcome of these matters or what impact, if any, the outcome of these matters might have on the Company’s consolidated financial position, results of operations or cash flows. Violations of export control or economic sanctions laws or regulations could result in a range of governmental enforcement actions, including fines or penalties, injunctions and/or criminal or other civil proceedings, which actions could have a material adverse effect on the Company’s reputation, business, financial condition and results of operations. At this time, no claims have been made against the Company.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity.

While the Company maintains general, products, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

Purchase Commitments

From time to time, the Company enters into long-term inventory purchase commitments with minimum purchase requirements for raw materials and finished goods to ensure the availability of products for production and distribution. These commitments may have a significant impact on levels of inventory maintained by the Company.

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, the use of terms such as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” and similar expressions identify forward-looking statements. All statements that address operating performance, events or developments that DENTSPLY International Inc. (“DENTSPLY” or the “Company”) expects or anticipates will occur in the future are forward-looking statements. Forward-looking statements are based on management’s current expectations and beliefs, and are inherently susceptible to uncertainty, risks, and changes in circumstances that could cause actual results to differ materially from the Company’s historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Part I, Item 1A (“Risk Factors”) of the Company’s Form 10-K for the year ended December 31, 2013 and those described from time to time in our future reports filed with the Securities and Exchange Commission. The Company undertakes no duty and has no obligation to update forward-looking statements as a result of future events or developments.

OVERVIEW

Highlights

- For the quarter ended September 30, 2014, worldwide internal sales growth was 2.4%, with positive internal growth in all major geographic regions. Internal growth in the U.S. was 2.0% for the quarter, while internal growth for Europe and the Rest of World regions were 1.0% and 5.9%, respectively.
- Third quarter 2014 earnings per diluted share of \$0.52 decreased by 5.5% from \$0.55 in the prior year period. On an adjusted basis (a non-GAAP measure), third quarter 2014 earnings per diluted share of \$0.62 grew 8.8% from \$0.57 in the same period in the prior year.
- Operating margin for the first nine months of 2014 was 15.5%, an increase of 90 basis points as compared to 14.6% for the first nine months of 2013.
- Operating cash flow for the nine months ended September 30, 2014 was \$367.8 million compared to \$258.3 million for the nine months ended September 30, 2013.

Company Profile

DENTSPLY International Inc. is a leading manufacturer and distributor of dental and other consumable medical device products. The Company believes it is the world’s largest manufacturer of consumable dental products for the professional dental market. For over 110 years, DENTSPLY’s commitment to innovation and professional collaboration has enhanced its portfolio of branded consumables and small equipment. Headquartered in the United States, the Company has global operations with sales in more than 120 countries. The Company also has strategically located distribution centers to enable it to better serve its customers and increase its operating efficiency. While the United States and Europe are the Company’s largest markets, the Company serves all major markets worldwide.

Principal Products

The Company has four principal product categories: 1) Dental Consumable Products; 2) Dental Laboratory Products; 3) Dental Specialty Products; and 4) Consumable Medical Device Products.

Dental consumable products consist of dental supplies and devices and small equipment used in dental offices for the treatment of patients. The Company manufactures thousands of different dental consumable products marketed under more than one hundred brand names. DENTSPLY’s dental consumable products within this category include dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners and topical fluoride. Small equipment products in the dental consumable category consist of various durable goods used in dental offices for treatment of patients. DENTSPLY’s small equipment products include dental handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

DENTSPLY's products in the dental laboratory products category include dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics and crown and bridge materials. Equipment in this category includes computer aided design and machining (CAD/CAM) ceramic systems and porcelain furnaces.

Dental specialty products are specialized treatment products used within the dental office and laboratory settings. DENTSPLY's products in this category include endodontic (root canal) instruments and materials, implants and related products, bone grafting materials, 3D digital scanning and treatment planning software, orthodontic appliances and accessories.

Consumable medical device products consist mainly of urology catheters, certain surgical products, medical drills and other non-medical products.

Principal Measurements

The principal measurements used by the Company in evaluating its business are: (1) internal sales growth by geographic region; (2) constant currency sales growth by geographic region; (3) operating margins of each reportable segment including product pricing and cost controls; (4) the development, introduction and contribution of innovative new products; and (5) sales growth through acquisition.

The Company defines "internal sales growth" as the increase or decrease in net sales from period to period, excluding (1) precious metal content; (2) the impact of changes in currency exchange rates; and (3) net acquisition sales growth. The Company defines "net acquisition sales growth" as the net sales, excluding precious metal content, for a period of twelve months following the transaction date of businesses that have been acquired, less the net sales, excluding precious metal content, for a period of twelve months prior to the transaction date of businesses that have been divested. The Company defines "constant currency sales growth" as internal sales growth plus net acquisition sales growth.

The primary drivers of internal growth includes global dental market growth, innovation and new products launched by the Company, and continued investments in sales and marketing resources, including clinical education. Management believes that over time, the Company's ability to execute its strategies allows it to grow at a modest premium to the growth rate of the underlying dental market. Management further believes that the global dental market has generally in the past and should over time in the future grow at a premium to underlying economic growth rates. Considering all of these factors, the Company assumes that the long-term growth rate for the dental market will range from 3% to 6% on average and that the Company targets a slight premium to market growth. Over the past several years, growth in the global dental and other healthcare markets have been restrained by lower economic growth in Western Europe and certain other markets compared to historical averages and, accordingly, market growth rates, and the Company's internal growth rate remains uncertain in the near term.

The Company's business is subject to quarterly fluctuations of consolidated net sales and net income. The Company typically implements most of its price changes at the beginning of the first or fourth quarters. Price changes, other marketing and promotional programs as well as the management of inventory levels by distributors and the implementation of strategic initiatives, may impact sales levels in a given period.

The Company also has a focus on maximizing operational efficiencies. Management continues to evaluate the consolidation of operations or functions to reduce costs. In addition, the Company remains focused on enhancing efficiency through expanded use of technology and process improvement initiatives. The Company believes that the benefits from these initiatives will improve the cost structure and help offset areas of rising costs such as energy, employee benefits and regulatory oversight and compliance. In connection with these efforts, the Company targets adjusted operating income margins to expand to 20% as the benefits of these initiatives are realized over time. In addition, the Company expects that it will record restructuring charges, from time to time, associated with such initiatives. These restructuring charges could be material to the Company's consolidated financial statements and there can be no assurance that the target adjusted operating income margins will be achieved. Consistent with these efforts, the Company recently announced it is proposing steps in Germany to reorganize elements of its laboratory business and associated manufacturing capabilities. The Company seeks to realign its portfolio of laboratory products, with increased focus on innovative prosthetics materials while deemphasizing its CAD/CAM equipment business. As required under German law, the Company has entered into a statutory co-determination process under which it will collaborate with the appropriate labor groups to jointly define the infrastructure and staffing adjustments necessary to support this initiative.

Product innovation is a key component of the Company's overall growth strategy. New advances in technology are anticipated to have a significant influence on future products in dentistry and consumable medical device markets in which the Company operates. As a result, the Company continues to pursue research and development initiatives to support technological development, including collaborations with various research institutions and dental schools. In addition, the Company licenses and purchases technologies developed by third parties. Although the Company believes these activities will lead to new innovative dental and

consumable medical device products, they involve new technologies and there can be no assurance that commercialized products will be developed.

The Company will continue to pursue opportunities to expand the Company's product offerings through acquisitions. Although the professional dental and the consumable medical device markets in which the Company operates have experienced consolidation, they remain fragmented. Management believes that there will continue to be adequate opportunities to participate as a consolidator in the industry for the foreseeable future.

Reclassification of Prior Year Amounts

Certain reclassifications have been made to prior year's data in order to conform to current year presentation. Specifically, during the first quarter of 2014, the Company realigned reporting responsibilities for multiple locations as a result of changes to the management reporting structure. The segment information reflects the revised structure for all periods shown.

RESULTS OF OPERATIONS, QUARTER ENDED SEPTEMBER 30, 2014 COMPARED TO QUARTER ENDED SEPTEMBER 30, 2013

Net Sales

Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a significant portion of DENTSPLY's net sales is comprised of sales of precious metals generated through sales of the Company's precious metal dental alloy products, which are used by third parties to construct crown and bridge materials. Due to the fluctuations of precious metal prices and because the precious metal content of the Company's sales is largely a pass-through to customers and has minimal effect on earnings, DENTSPLY reports net sales both with and without precious metal content to show the Company's performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change.

The presentation of net sales, excluding precious metal content, is considered a measure not calculated in accordance with the generally accepted accounting principles in the United States ("US GAAP"), and is therefore considered a non-US GAAP measure. The Company provides the following reconciliation of net sales to net sales, excluding precious metal content. The Company's definitions and calculations of net sales, excluding precious metal content, and other operating measures derived using net sales, excluding precious metal content, may not necessarily be the same as those used by other companies.

| (in millions) | Three Months Ended | | \$ Change | % Change |
|---|--------------------|----------|-----------|----------|
| | 2014 | 2013 | | |
| Net sales | \$ 708.2 | \$ 704.0 | \$ 4.2 | 0.6% |
| Less: precious metal content of sales | 26.7 | 34.6 | (7.9) | (22.8%) |
| Net sales, excluding precious metal content | \$ 681.5 | \$ 669.4 | \$ 12.1 | 1.8 % |

Net sales, excluding precious metal content, for the three months ended September 30, 2014 were \$681.5 million, an increase of \$12.1 million over the third quarter of 2013. The change in net sales, excluding precious metal content, was primarily a result of 3.0% of constant currency sales growth partially offset by 1.2% of unfavorable foreign currency translation. Precious metal content of sales declined mostly as a result of lower refinery volume compared to the same period a year ago.

Constant Currency and Internal Sales Growth

The following table includes growth rates for net sales, excluding precious metal content, for the three months ended September 30, 2014 compared with the three months ended September 30, 2013.

| | Three Months Ended September 30, 2014 | | | |
|--------------------------------|---------------------------------------|--------|---------------|-----------|
| | United States | Europe | Rest of World | Worldwide |
| Internal sales growth | 2.0% | 1.0% | 5.9% | 2.4% |
| Acquisition sales growth | 0.3% | 0.1% | 2.5% | 0.6% |
| Constant currency sales growth | 2.3% | 1.1% | 8.4% | 3.0% |

United States

Net sales, excluding precious metal content, increased by 2.3% on a constant currency basis in the third quarter of 2014 as compared to the third quarter of 2013. Internal sales growth was led by increased sales in dental consumable and dental laboratory products partially offset by lower sales of a consumable medical device product that was in-sourced by a customer.

Europe

Net sales, excluding precious metal content, increased by 1.1% on a constant currency sales growth basis in the third quarter of 2014 as compared to the third quarter of 2013. Internal sales growth was led by increased sales in consumable medical device products partially offset by decreased sales in dental laboratory products. The geopolitical instability within the CIS region continues to negatively impact sales growth in the European region. Excluding sales in the CIS, constant currency sales growth would have increased 2.4% for the three months ended September 30, 2014 compared to the same period in 2013, led by increased sales in consumable medical device and dental specialty products.

Rest of World

Net sales, excluding precious metal content, increased by 8.4% on a constant currency sales growth basis in the third quarter of 2014 as compared to the third quarter of 2013. Internal and acquisition sales growth were led by dental specialty products category.

Gross Profit

| (in millions) | Three Months Ended | | | |
|---|--------------------|----------|-----------|----------|
| | September 30, | | \$ Change | % Change |
| 2014 | 2013 | | | |
| Gross profit | \$ 388.1 | \$ 376.4 | \$ 11.7 | 3.1% |
| Gross profit as a percentage of net sales, including precious metal content | 54.8% | 53.5% | | |
| Gross profit as a percentage of net sales, excluding precious metal content | 56.9% | 56.2% | | |

Gross profit as a percentage of net sales, excluding precious metal content, increased by 70 basis points for the quarter ended September 30, 2014 compared to the same three month period ended September 30, 2013. The increase in the gross profit rate was primarily the result of favorable net pricing and positive product mix, compared to the same three month period in 2013.

Operating Expenses

| (in millions) | Three Months Ended | | | |
|---|--------------------|----------|-----------|----------|
| | September 30, | | | |
| | 2014 | 2013 | \$ Change | % Change |
| Selling, general and administrative expenses ("SG&A") | \$ 276.0 | \$ 269.2 | \$ 6.8 | 2.5% |
| Restructuring and other costs | 2.5 | 2.2 | 0.3 | 13.6% |
| SG&A as a percentage of net sales, including precious metal content | 39.0% | 38.2% | | |
| SG&A as a percentage of net sales, excluding precious metal content | 40.5% | 40.2% | | |

SG&A Expenses

SG&A expenses as a percentage of net sales, excluding precious metal content, for the quarter ended September 30, 2014 increased 30 basis points compared to the quarter end September 30, 2013. The increase is primarily related to higher professional fees in the period.

Other Income and Expense

| (in millions) | Three Months Ended | | |
|--------------------------------|--------------------|---------|--------|
| | September 30, | | |
| | 2014 | 2013 | Change |
| Net interest expense | \$ 11.3 | \$ 9.3 | \$ 2.0 |
| Other expense (income), net | 0.8 | 1.6 | (0.8) |
| Net interest and other expense | \$ 12.1 | \$ 10.9 | \$ 1.2 |

Net Interest Expense

Net interest expense for the three months ended September 30, 2014 was \$2.0 million higher compared to the three months ended September 30, 2013. The net increase is the result of a decline in non-cash fair value adjustments on net investment hedges in the three months period ended September 30, 2014 as compared to the same period in 2013, partially offset by reduced interest expense as a result of lower average debt levels.

Other Expense (Income), Net

Other expense (income), net for the three months ended September 30, 2014 was \$0.8 million lower compared to the three months ended September 30, 2013. Other expense (income), net in the three months ended September 30, 2014 of \$0.8 million is comprised primarily of \$0.7 million of interest and non-cash fair value adjustments on cross currency basis swaps not designated as hedges that offset currency risk on intercompany loans and \$0.8 million of currency transaction losses and \$0.7 million of other expense. Other expense (income), net in the third quarter of 2013 of \$1.6 million was comprised primarily of \$0.8 million of non-cash charges relating to cross currency basis swaps not designated as hedges that offset currency risk on intercompany loans, \$0.2 million of currency transaction losses and \$0.6 million of other expense.

Income Taxes and Net Income

| (in millions, except per share data) | Three Months Ended September 30, | | \$ Change |
|---|-------------------------------------|----------|-----------|
| | 2014 | 2013 | |
| Effective income tax rate | 21.8% | 14.0% | |
| Equity in net loss of unconsolidated affiliated company | \$ (1.0) | \$ (0.1) | \$ (0.9) |
| Net income attributable to noncontrolling interests | \$ — | \$ 1.0 | \$ (1.0) |
| Net income attributable to DENTSPLY International | \$ 75.3 | \$ 79.9 | \$ (4.6) |
| Earnings per common share - diluted | \$ 0.52 | \$ 0.55 | |

Provision for Income Taxes

The Company's effective tax rate for the third quarter of 2014 and 2013 was 21.8% and 14.0%, respectively. During the third quarter of 2013, the Company recorded a favorable impact to the tax rate of \$6.2 million related to prior year tax matters. For the three months ended September 30, 2014, the effective tax rate was unfavorably impacted by the Company's change in the mix of consolidated earnings compared to the same period in the prior year.

The Company's effective income tax rate for 2014 includes the net favorable impact of amortization on purchased intangibles assets, income related to credit risk adjustments on outstanding derivatives, integration and restructuring and other costs, and various income tax adjustments which impacted income before income taxes and the provision for income taxes by \$19.0 million and \$5.3 million, respectively.

In 2013, the Company's effective income tax rate included the net favorable impact of amortization on purchased intangibles assets, restructuring and other costs, income related to credit risk adjustments on outstanding derivatives and various income tax adjustments which impacted income before income taxes and the provision for income taxes by \$13.9 million and \$10.7 million, respectively.

Equity in net loss of unconsolidated affiliated company

The Company's 17% ownership investment of DIO Corporation ("DIO") resulted in a net loss of \$1.0 million and \$0.1 million on an after-tax basis for the third quarter of 2014 and 2013, respectively. The equity earnings of DIO include the result of mark-to-market changes related to the derivative accounting for the convertible bonds issued by DIO to DENTSPLY. The Company's portion of the mark-to-market loss recorded through DIO's net income for the third quarter of 2014 was approximately \$0.2 million and for the third quarter of 2013, the mark-to-market gain recorded by DIO was approximately \$0.8 million.

Net income attributable to noncontrolling interests

The portion of consolidated net income attributable to noncontrolling interests decreased \$1.0 million for the three months ended September 30, 2014 as compared to the same three month period in 2013 as a result of the contractual purchase of the remaining shares of a variable interest entity effective January 1, 2014. The Company anticipates the cash outflow for this purchase to be later in 2014 or early 2015.

Net Income attributable to DENTSPLY International

In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share. The Company discloses adjusted net income attributable to DENTSPLY International to allow investors to evaluate the performance of the Company's operations exclusive of certain items that impact the comparability of results from period to period and certain large non-cash charges related to purchased intangible assets. The Company believes that this information is helpful in understanding underlying operating trends and cash flow generation. The adjusted net income attributable to DENTSPLY International consists of net income attributable to DENTSPLY International adjusted to exclude the impact of the following:

(1) *Acquisition related costs.* These adjustments include costs related to integrating recently acquired businesses and specific costs related to the consummation of the acquisition process. These costs are irregular in timing and as such may not be indicative of past and future performance of the Company and are therefore excluded to allow investors to better understand underlying operating trends.

(2) *Restructuring and other costs.* These adjustments include both costs and income that are irregular in timing, amount and impact to the Company's financial performance. As such, these items may not be indicative of past and future performance of the Company and are therefore excluded for the purpose of understanding underlying operating trends.

(3) *Amortization of purchased intangible assets.* This adjustment excludes the periodic amortization expense related to purchased intangible assets. Beginning in 2011, the Company began recording large non-cash charges related to the values attributed to purchased intangible assets. These charges have been excluded from adjusted net income attributed to DENTSPLY International to allow investors to evaluate and understand operating trends excluding these large non-cash charges.

(4) *Income related to credit risk and fair value adjustments.* These adjustments include both the cost and income impacts of adjustments in certain assets and liabilities that are recorded through net income which are due solely to the changes in fair value and credit risk. These items can be variable and driven more by market conditions than the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

(5) *Certain fair value adjustments related to an unconsolidated affiliated company.* This adjustment represents the fair value adjustment of the unconsolidated affiliated company's convertible debt instrument held by the Company. The affiliate is accounted for under the equity method of accounting. The fair value adjustment is driven by open market pricing of the affiliate's equity instruments, which has a high degree of variability and may not be indicative of the operating performance of the affiliate or the Company.

(6) *Income tax related adjustments.* These adjustments include both income tax expenses and income tax benefits that are representative of income tax adjustments mostly related to prior periods, as well as the final settlement of income tax audits. These adjustments are irregular in timing and amount and may significantly impact the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

Adjusted earnings per diluted common share is calculated by dividing adjusted net income attributable to DENTSPLY International by diluted weighted-average common shares outstanding. Adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures. These non-US GAAP measures may differ from other companies. Income tax related adjustments may include the impact to adjust the interim effective income tax rate to the expected annual effective tax rate. The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

| (in thousands, except per share amounts) | Three Months Ended September 30, 2014 | |
|--|--|--------------------------------|
| | Net Income | Per Diluted Common Share |
| Net income attributable to DENTSPLY International | \$ 75,273 | \$ 0.52 |
| Amortization of purchased intangible assets, net of tax | 8,417 | 0.06 |
| Restructuring and other costs, net of tax | 2,524 | 0.02 |
| Acquisition related activities, net of tax | 1,394 | 0.01 |
| Credit risk and fair value adjustments to outstanding derivatives, net of tax | 817 | 0.01 |
| Income tax related adjustments | 595 | — |
| Loss on fair value adjustments related to an unconsolidated affiliated company, net of tax | 243 | — |
| Adjusted non-US GAAP earnings | <u>\$ 89,263</u> | <u>\$ 0.62</u> |

| (in thousands, except per share amounts) | Three Months Ended September 30, 2013 | |
|--|--|--------------------------------|
| | Net Income | Per Diluted Common Share |
| Net income attributable to DENTSPLY International | \$ 79,851 | \$ 0.55 |
| Amortization of purchased intangible assets, net of tax | 7,851 | 0.06 |
| Restructuring and other costs, net of tax | 1,961 | 0.01 |
| Acquisition related activities, net of tax | 744 | 0.01 |
| Credit risk and fair value adjustments to outstanding derivatives, net of tax | (488) | — |
| Gain on fair value adjustments at an unconsolidated affiliated company, net of tax | (829) | (0.01) |
| Income tax related adjustments | (6,882) | (0.05) |
| Adjusted non-US GAAP earnings | <u>\$ 82,208</u> | <u>\$ 0.57</u> |

Operating Segment Results

Third Party Net Sales, Excluding Precious Metal Content

| (in millions) | Three Months Ended September 30, | | | |
|--|-------------------------------------|----------|-----------|----------|
| | 2014 | 2013 | \$ Change | % Change |
| Dental Consumable and Certain International Businesses | \$ 182.8 | \$ 172.3 | \$ 10.5 | 6.1% |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | \$ 360.6 | \$ 368.9 | \$ (8.3) | (2.2%) |
| Healthcare and Emerging Markets Businesses | \$ 139.3 | \$ 129.3 | \$ 10.0 | 7.7% |

Segment Operating Income

| (in millions) | Three Months Ended September 30, | | | |
|--|-------------------------------------|---------|-----------|----------|
| | 2014 | 2013 | \$ Change | % Change |
| Dental Consumable and Certain International Businesses | \$ 69.1 | \$ 61.9 | \$ 7.2 | 11.6% |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | \$ 57.5 | \$ 62.1 | \$ (4.6) | (7.4%) |
| Healthcare and Emerging Markets Businesses | \$ 9.8 | \$ 6.2 | \$ 3.6 | 58.1% |

Dental Consumable and Certain International Businesses

Net sales, excluding precious metal content, increased \$10.5 million, or 6.1% for the three months ended September 30, 2014 as compared to the same period in 2013. On a constant currency basis, net sales, excluding precious metal content, increased 6.7% as compared to 2013 reflecting sales growth across all businesses as well as the benefit of recent acquisitions.

Operating income increased \$7.2 million, or 11.6% for the three months ended September 30, 2014 as compared to 2013. The increase in operating income was primarily the result of sales growth and improved gross margins within these businesses.

Dental Specialty and Laboratory and Certain Global Distribution Businesses

Net sales, excluding precious metal content, decreased \$8.3 million, or 2.2% for the three months ended September 30, 2014 compared to 2013. On a constant currency basis, net sales, excluding precious metal content, decreased 0.8% as compared to 2013 due to sales declines in the dental laboratory and global distribution businesses partially offset by sales growth in dental specialty businesses.

Operating income decreased \$4.6 million compared to 2013, primarily due to lower sales in 2014.

Healthcare and Emerging Markets Businesses

Net sales, excluding precious metal content, increased \$10.0 million, or 7.7% for the three months ended September 30, 2014 as compared to 2013. On a constant currency basis, net sales, excluding precious metal content, increased 9.1% as compared to 2013. The growth was primarily due to increased sales in the emerging markets businesses and, to a lesser extent, the healthcare business.

Operating income improved \$3.6 million during the three months ended September 30, 2014 as compared to 2013 primarily due to stronger sales and improved operating expense rates within these businesses.

RESULTS OF OPERATIONS, NINE MONTHS ENDED SEPTEMBER 30, 2014 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2013

Net Sales

| (in millions) | Nine Months Ended September 30, | | \$ Change | % Change |
|---|------------------------------------|------------|-----------|----------|
| | 2014 | 2013 | | |
| Net sales | \$ 2,203.6 | \$ 2,197.1 | \$ 6.5 | 0.3% |
| Less: precious metal content of sales | 101.9 | 139.1 | (37.2) | (26.7%) |
| Net sales, excluding precious metal content | \$ 2,101.7 | \$ 2,058.0 | \$ 43.7 | 2.1 % |

Net sales, excluding precious metal content, for the nine months ended September 30, 2014 were \$2,101.7 million, an increase of \$43.7 million compared to the nine months ended September 30, 2013. The change in net sales, excluding precious metal content, was a result of 1.7% constant currency sales growth. Precious metal content of sales declined mostly as a result of lower refinery volume compared to the same period a year ago.

Constant Currency and Internal Sales Growth

The following table includes growth rates for net sales, excluding precious metal content, for the nine months ended September 30, 2014 compared with the nine months ended September 30, 2013.

| | Nine Months Ended September 30, 2014 | | | |
|--------------------------------|--------------------------------------|--------|---------------|-----------|
| | United States | Europe | Rest of World | Worldwide |
| Internal sales growth | 0.8% | (0.6%) | 4.5% | 0.9% |
| Acquisition sales growth | 0.3% | 0.1 % | 2.9% | 0.8% |
| Constant currency sales growth | 1.1% | (0.5%) | 7.4% | 1.7% |

United States

Net sales, excluding precious metal content, increased by 1.1% on a constant currency sales growth basis for the nine months ended September 30, 2014 as compared to the same nine month period of 2013. Internal sales growth was led by increased sales in the dental consumable product category, partially offset by lower sales of a consumable medical device product that was in-sourced by a customer.

Europe

Net sales, excluding precious metal content, decreased by 0.5% on a constant currency sales growth basis for the nine months ended September 30, 2014 as compared to the same nine months ended September 30, 2013, reflecting a continuing decline in sales within the CIS countries. Excluding sales in the CIS, constant currency sales growth would have increased 1.1% for the nine months ended September 30, 2014 compared to the same period in 2013, led by increased sales in consumable medical device and dental specialty products.

Rest of World

Net sales, excluding precious metal content, increased by 7.4% on a constant currency sales growth basis for the nine months ended September 30, 2014 as compared to the nine months ended September 30, 2013. Internal sales and acquisition growth was led by the dental specialty products category.

Gross Profit

| (in millions) | Nine Months Ended September 30, | | | |
|---|------------------------------------|------------|-----------|----------|
| | 2014 | 2013 | \$ Change | % Change |
| Gross profit | \$ 1,206.7 | \$ 1,179.6 | \$ 27.1 | 2.3% |
| Gross profit as a percentage of net sales, including precious metal content | 54.8% | 53.7% | | |
| Gross profit as a percentage of net sales, excluding precious metal content | 57.4% | 57.3% | | |

Gross profit as a percentage of net sales, excluding precious metal content, increased 10 basis points for the nine month period ended September 30, 2014 compared to the nine months end September 30, 2013. The increase in the gross profit rate was primarily the result of favorable net pricing compared to the same nine month period in 2013.

Operating Expenses

| (in millions) | Nine Months Ended September 30, | | | |
|---|------------------------------------|----------|-----------|----------|
| | 2014 | 2013 | \$ Change | % Change |
| Selling, general and administrative expenses ("SG&A") | \$ 859.9 | \$ 852.8 | \$ 7.1 | 0.8% |
| Restructuring and other costs | 4.5 | 5.1 | (0.6) | (11.8%) |
| SG&A as a percentage of net sales, including precious metal content | 39.0% | 38.8% | | |
| SG&A as a percentage of net sales, excluding precious metal content | 40.9% | 41.4% | | |

SG&A Expenses

SG&A expenses as a percentage of net sales, excluding precious metal content, decreased 50 basis points in the nine months ended September 30, 2014 when compared to the same period ended September 30, 2013. The rate decrease is primarily due to cost reduction initiatives and expense controls across a number of businesses, as well as higher expenses recorded in the first three months of 2013 relating to trade shows.

Other Income and Expense

| (in millions) | Nine Months Ended September 30, | | | Change |
|--------------------------------|------------------------------------|---------|----------|--------|
| | 2014 | 2013 | | |
| Net interest expense | \$ 30.8 | \$ 31.6 | \$ (0.8) | |
| Other expense (income), net | 1.8 | 8.7 | (6.9) | |
| Net interest and other expense | \$ 32.6 | \$ 40.3 | \$ (7.7) | |

Net Interest Expense

Net interest expense for the nine month period ended September 30, 2014 was \$0.8 million lower compared to the nine months ended September 30, 2013. The net decrease is a result of a \$3.7 million decrease in interest expense due to lower average debt levels in 2014 compared to the prior year period, largely offset by \$3.0 million decrease in investment income due to lower balances of cross currency basis swaps designated as net investment hedges compared to the same nine month period in 2013.

Other Expense (Income), Net

Other expense (income), net for the nine months ended September 30, 2014 was \$6.9 million lower compared to the nine months ended September 30, 2013. Other expense (income), net for the nine months ended September 30, 2014 was \$1.8 million comprised primarily of \$0.8 million income of interest and non-cash fair value adjustments on cross currency basis swaps not designated as hedges that offset currency risk on intercompany loans, \$1.4 million of currency transaction losses and \$1.2 million of other expense. Other expense (income), net for the nine months ended September 30, 2013 was \$8.7 million, comprised primarily of \$6.4 million of interest and non-cash fair value adjustments on cross currency basis swaps not designated as hedges that offset currency risk on intercompany loans, \$1.5 million of currency transaction losses and \$0.8 million of other expense.

Income Taxes and Net Income

| (in millions, except per share data) | Nine Months Ended September 30, | | |
|--|---------------------------------|----------|-----------|
| | 2014 | 2013 | \$ Change |
| Effective income tax rate | 22.6% | 14.1% | |
| Equity in net (loss) income of unconsolidated affiliated company | \$ (1.6) | \$ 0.3 | \$ (1.9) |
| Net income attributable to noncontrolling interests | \$ 0.1 | \$ 3.4 | \$ (3.3) |
| Net income attributable to DENTSPLY International | \$ 238.1 | \$ 238.8 | \$ (0.7) |
| Earnings per common share - diluted | \$ 1.65 | \$ 1.65 | |

Provision for Income Taxes

The Company's effective tax rate for the nine month period of 2014 and 2013 was 22.6% and 14.1%, respectively. In the 2013 period, the Company recorded a tax benefit of \$9.4 million related to U.S. federal legislative changes enacted in January 2013, relating to 2012, and \$9.3 million of benefits related to prior year tax matters. In the nine months ended September 30, 2014, the effective tax rate was unfavorably impacted by the Company's change in the mix of consolidated earnings as compared to the same period in the prior year.

The Company's effective income tax rate for 2014 includes the net favorable impact of amortization on purchased intangibles assets, income related to credit risk adjustments on outstanding derivatives, integration and restructuring and other costs, and various income tax adjustments, which impacted income before income taxes and the provision for income taxes by \$48.1 million and \$11.0 million, respectively.

In 2013, the Company's effective income tax rate included the net favorable impact of amortization on purchased intangibles assets, income related to credit risk adjustments on outstanding derivatives, integrating and restructuring and other costs and various income tax adjustments which impacted income before income taxes and the provision for income taxes by \$48.8 million and \$33.0 million, respectively.

Equity in net (loss) income of unconsolidated affiliated company

The Company's 17% ownership investment of DIO Corporation ("DIO") resulted in a net loss of \$1.6 million on an after-tax basis for the nine months end September 30, 2014 and net income of \$0.3 million on an after-tax basis for the nine months ended September 30, 2013. The equity earnings of DIO include the result of mark-to-market changes related to the derivative accounting for the convertible bonds issued by DIO to DENTSPLY. The Company's portion of the mark-to-market gains recorded through DIO's net income for the nine month period in 2014 and 2013 was approximately \$0.9 million and \$1.3 million, respectively.

Net income attributable to noncontrolling interests

The portion of consolidated net income attributable to noncontrolling interests decreased \$3.3 million for the nine months ended September 30, 2014 as compared to the same period in 2013 as a result of the contractual purchase of the remaining shares of a variable interest entity effective January 1, 2014. The Company anticipates the cash outflow for this purchase to be later in 2014 or early 2015.

Net Income attributable to DENTSPLY International

In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share. The Company discloses adjusted net income attributable to DENTSPLY International to allow investors to evaluate the performance of the Company's operations exclusive of certain items that impact the comparability of results from period to period and certain large non-cash charges related to purchased intangible assets. The Company believes that this information is helpful in understanding underlying operating trends and cash flow generation. The adjusted net income attributable to DENTSPLY International consists of net income attributable to DENTSPLY International adjusted to exclude the impact of the following:

(1) *Acquisition related costs.* These adjustments include costs related to integrating recently acquired businesses and specific costs related to the consummation of the acquisition process. These costs are irregular in timing and as such may not be indicative of past and future performance of the Company and are therefore excluded to allow investors to better understand underlying operating trends.

(2) *Restructuring and other costs.* These adjustments include both costs and income that are irregular in timing, amount and impact to the Company's financial performance. As such, these items may not be indicative of past and future performance of the Company and are therefore excluded for the purpose of understanding underlying operating trends.

(3) *Amortization of purchased intangible assets.* This adjustment excludes the periodic amortization expense related to purchased intangible assets. Beginning in 2011, the Company began recording large non-cash charges related to the values attributed to purchased intangible assets. These charges have been excluded from adjusted net income attributed to DENTSPLY International to allow investors to evaluate and understand operating trends excluding these large non-cash charges.

(4) *Income related to credit risk and fair value adjustments.* These adjustments include both the cost and income impacts of adjustments in certain assets and liabilities that are recorded through net income which are due solely to the changes in fair value and credit risk. These items can be variable and driven more by market conditions than the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

(5) *Certain fair value adjustments related to an unconsolidated affiliated company.* This adjustment represents the fair value adjustment of the unconsolidated affiliated company's convertible debt instrument held by the Company. The affiliate is accounted for under the equity method of accounting. The fair value adjustment is driven by open market pricing of the affiliate's equity instruments, which has a high degree of variability and may not be indicative of the operating performance of the affiliate or the Company.

(6) *Income tax related adjustments.* These adjustments include both income tax expenses and income tax benefits that are representative of income tax adjustments mostly related to prior periods, as well as the final settlement of income tax audits. These adjustments are irregular in timing and amount and may significantly impact the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

Adjusted earnings per diluted common share is calculated by dividing adjusted net income attributable to DENTSPLY International by diluted weighted-average common shares outstanding. Adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures. These non-US GAAP measures may differ from other companies. Income tax related adjustments may include the impact to adjust the interim effective income tax rate to the expected annual effective tax rate. The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

| (in thousands, except per share amounts) | Nine Months Ended September 30, 2014 | |
|--|---|--------------------------------|
| | Net Income | Per Diluted Common Share |
| Net income attributable to DENTSPLY International | \$ 238,144 | \$ 1.65 |
| Amortization of purchased intangible assets, net of tax | 25,648 | 0.18 |
| Restructuring and other costs, net of tax | 4,112 | 0.03 |
| Acquisition related activities, net of tax | 3,740 | 0.02 |
| Income tax-related adjustments | 3,536 | 0.02 |
| Credit risk and fair value adjustments to outstanding derivatives, net of tax | 15 | — |
| Gain on fair value adjustments related to an unconsolidated affiliated company, net of tax | (792) | — |
| Adjusted non-US GAAP earnings | <u>\$ 274,403</u> | <u>\$ 1.90</u> |

| (in thousands, except per share amounts) | Nine Months Ended September 30, 2013 | |
|--|---|--------------------------------|
| | Net Income | Per Diluted Common Share |
| Net income attributable to DENTSPLY International | \$ 238,763 | \$ 1.65 |
| Amortization of purchased intangible assets, net of tax | 24,229 | 0.17 |
| Restructuring and other costs, net of tax | 4,462 | 0.03 |
| Acquisition related activities, net of tax | 2,843 | 0.02 |
| Credit risk and fair value adjustments to outstanding derivatives, net of tax | 2,702 | 0.02 |
| Gain on fair value adjustments at an unconsolidated affiliated company, net of tax | (1,347) | (0.01) |
| Income tax related adjustments | (18,388) | (0.13) |
| Adjusted non-US GAAP earnings | <u>\$ 253,264</u> | <u>\$ 1.75</u> |

Operating Segment Results

Third Party Net Sales, Excluding Precious Metal Content

| (in millions) | Nine Months Ended September 30, | | \$ Change | % Change |
|--|------------------------------------|------------|-----------|----------|
| | 2014 | 2013 | | |
| Dental Consumable and Certain International Businesses | \$ 540.4 | \$ 506.5 | \$ 33.9 | 6.7% |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | \$ 1,160.9 | \$ 1,171.2 | \$ (10.3) | (0.9%) |
| Healthcare and Emerging Markets Businesses | \$ 403.8 | \$ 383.6 | \$ 20.2 | 5.3% |

Segment Operating Income

| (in millions) | Nine Months Ended September 30, | | | |
|--|------------------------------------|----------|-----------|----------|
| | 2014 | 2013 | \$ Change | % Change |
| Dental Consumable and Certain International Businesses | \$ 193.8 | \$ 176.1 | \$ 17.7 | 10.1% |
| Dental Specialty and Laboratory and Certain Global Distribution Businesses | \$ 211.0 | \$ 211.6 | \$ (0.6) | (0.3%) |
| Healthcare and Emerging Markets Businesses | \$ 24.5 | \$ 16.3 | \$ 8.2 | 50.3% |

Dental Consumable and Certain International Businesses

Net sales, excluding precious metal content, increased \$33.9 million, or 6.7% for the nine months ended September 30, 2014 compared to the same period in 2013. On a constant currency basis, net sales, excluding precious metal content, increased 6.1% as compared to the same period in 2013 reflecting balanced growth across all businesses as well as the benefit of recent acquisitions.

Operating income increased \$17.7 million, or 10.1% for the nine months ended September 30, 2014 compared to 2013. The improvement in operating income was primarily the result of sales growth and improved gross margins within the businesses.

Dental Specialty and Laboratory and Certain Global Distribution Businesses

Net sales, excluding precious metal content, decreased \$10.3 million for the nine months ended September 30, 2014 compared to 2013. On a constant currency basis, net sales, excluding precious metal content, decreased 1.4% as compared to the same period in 2013 due to sales declines in the dental laboratory and dental specialty businesses partially offset by sales growth in the global distribution businesses.

Operating income decreased \$0.6 million compared to the same period in 2013, primarily due to sales declines mostly offset by the effects of positive foreign currency translation.

Healthcare and Emerging Markets Businesses

Net sales, excluding precious metal content, increased \$20.2 million, or 5.3% for the nine months ended September 30, 2014 compared to 2013. On a constant currency basis, net sales, excluding precious metal content, increased 5.2% when compared to the same period of 2013 reflecting balanced improvements in both the healthcare and emerging markets businesses.

Operating income improved \$8.2 million during the nine months ended September 30, 2014 compared to 2013 primarily due to increased sales and lower expense rates.

CRITICAL ACCOUNTING POLICIES

Except as noted below, there have been no other significant material changes to the critical accounting policies as disclosed in the Company's Form 10-K for the year ended December 31, 2013.

Annual Goodwill and Indefinite-Lived Assets Impairment Testing

Goodwill

Goodwill is not amortized; instead, it is tested for impairment annually or more frequently if indicators of impairment exist or if a decision is made to sell a business. The valuation date for annual impairment testing is April 30.

The performance of the Company's 2014 annual impairment test did not result in any impairment of the Company's goodwill. The weighted average cost of capital ("WACC") rates utilized in the 2014 analysis ranged from 8.6% to 14.0%. If the WACC rate of each of the Company's reporting units been hypothetically increased by 100 basis points at April 30, 2014, the fair value of those reporting units would still exceed net book value. If the fair value of each of the Company's reporting units had been hypothetically reduced by 5% at April 30, 2014, the fair value of those reporting units would still exceed net book value. If the fair value of each of the Company's reporting units had been hypothetically reduced by 10% at April 30, 2014, due to competitive

conditions, one reporting unit within the Dental Specialty and Laboratory and Certain Global Distribution Businesses segment would have a net book value exceeding its fair value by approximately \$5.9 million.

At September 30, 2014, the Company updated its goodwill impairment testing for the reporting unit noted above as well as for one reporting unit in the Healthcare and Emerging Markets Business segment based on current year financial performance. The review did not result in any impairment of the reporting units' respective goodwill balances. Assumptions used in the calculations of fair value were substantially consistent with those at April 30, 2014. If the WACC rate of these two reporting units had been hypothetically increased by 100 basis points at September 30, 2014, the fair value of these reporting units would still exceed net book value. If the fair value of these reporting units had been hypothetically reduced by 5%, the reporting unit within the Healthcare and Emerging Markets Businesses segment would have had a net book value exceeding its fair value by approximately \$0.5 million. If the fair value of these reporting units had been hypothetically reduced by 10% at September 30, 2014, both reporting units would have net book values exceeding their fair values by approximately \$4.0 million each. Goodwill for the two reporting units totals \$148.2 million at September 30, 2014. To the extent that future operating results of these reporting units do not meet the forecasted cash flows the Company can provide no assurance that a future goodwill impairment charge would not be incurred.

Indefinite-Lived Assets

Indefinite-lived intangible assets consist of tradenames and are not subject to amortization; instead, they are tested for impairment annually or more frequently if indicators of impairment exist or if a decision is made to sell a business. The valuation date for annual impairment testing is April 30.

The performance of the Company's 2014 annual impairment test did not result in any impairment of the Company's indefinite-lived assets. If the fair value of each of the Company's indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 50 basis points at April 30, 2014, the fair value of these assets would still exceed their book value.

LIQUIDITY AND CAPITAL RESOURCES

Nine months ended September 30, 2014

Cash flow from operating activities during the nine months ended September 30, 2014 was \$367.8 million compared to \$258.3 million during the nine months ended September 30, 2013. The improvement in the first nine months' cash from operations of \$109.5 million was primarily the result of substantially lower cash taxes paid and lower working capital increases in accounts receivable and inventory as compared to the year ago period. The Company's cash and cash equivalents increased by \$22.7 million to \$97.7 million during the nine months ended September 30, 2014.

For the nine months ended September 30, 2014, the number of days for sales outstanding in accounts receivable increased by six days to 62 days as compared to 56 days at December 31, 2013 and decreased by two days compared to the same period in 2013. On a constant currency basis, the number of days of sales in inventory were 119 days at September 30, 2014 as compared to 123 days at June 30, 2014, 114 days at December 31, 2013 and 118 days at September 30, 2013. Through midyear 2014, the Company strategically increased inventory in a few businesses as part of transition plans associated with anticipated operational changes. The Company anticipates that inventory levels will continue to gradually return to more normal levels by the end of 2015.

The cash outflows for investing activities during the first nine months of 2014 were \$76.4 million, including capital expenditures of \$73.0 million. The Company expects capital expenditures to be approximately \$110.0 million for the full year 2014.

At September 30, 2014, the Company had authorization to maintain up to 34.0 million shares of treasury stock under the stock repurchase program as approved by the Board of Directors. Under this program, the Company repurchased 1.5 million shares during the first nine months of 2014 for \$70.8 million. As of September 30, 2014, the Company held 21.1 million shares of treasury stock. The Company received proceeds of \$18.7 million as a result of the exercise of 0.6 million of stock options during the nine months ended September 30, 2014.

The Company's total borrowings decreased by a net \$195.2 million during the nine months ended September 30, 2014, which includes a decrease of \$9.5 million due to exchange rate fluctuations on debt denominated in foreign currencies. At September 30, 2014, the Company's ratio of total net debt to total capitalization was 32.2% compared to 35.2% at December 31, 2013. The Company defines net debt as total debt, including current and long-term portions, less cash and cash equivalents and total capitalization as the sum of net debt plus equity.

On February 19, 2014, the Company refinanced a portion of the first required payment of \$75.0 million under the Private Placement Notes due February 2016 by issuing commercial paper. The second required payment of \$100.0 million under the Private Placement Notes is due in February 2015 and has been classified as current on the balance sheet.

On July 23, 2014, the Company entered into an Amended and Extended Revolving Credit Agreement to replace the 2011 Revolving Credit Agreement dated August 27, 2011, that had provided for a multi-currency revolving credit facility in an aggregate amount of up to \$500.0 million through July 27, 2016. The new Credit Agreement provides for a new five year, \$500.0 million multi-currency revolving credit facility through July 23, 2019 (the "Facility") to provide working capital from time to time for the Company.

On August 26, 2014, the Company repaid the first annual principal amortization of \$8.8 million representing a 5% mandatory principal amortization due in each of the first six years under the terms of the PNC Term Loan with a final maturity of August 26, 2020. The second annual installment in the amount of \$8.8 million will be due in August 2015 and has been classified as current on the balance sheet.

On September 29, 2014, the Company entered into a new Samurai Loan Agreement to replace the maturing Samurai Loan Agreement dated August 27, 2011, in an aggregate amount of 12.6 billion Japanese yen. The new Samurai Loan Agreement ("Samurai Loan") provides for a new five-year, 12.6 billion Japanese yen term loan through September 30, 2019. The Samurai Loan is designated as a net investment hedge. The Samurai Loan is unsecured and contains certain affirmative and negative covenants relating to the Company's operations and financial condition, including prescribed leverage and interest coverage ratios. The Samurai Loan contains customary events of default. Upon the occurrence of an event of default, all outstanding borrowings under the Samurai Loan may be accelerated and become immediately due and payable.

Under its five-year multi-currency revolving credit agreement, the Company is able to borrow up to \$500.0 million through July 23, 2019. The facility is unsecured and contains certain affirmative and negative covenants relating to the operations and financial condition of the Company. The most restrictive of these covenants pertain to asset dispositions and prescribed ratios of indebtedness to total capital and operating income plus depreciation and amortization to interest expense. At September 30, 2014, the Company was in compliance with these covenants. The Company also has available an aggregate \$500.0 million under a U.S. dollar commercial paper facility. The five-year revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facilities in the aggregate is \$500.0 million. At September 30, 2014, the Company had no outstanding borrowings under the multi-currency revolving facility.

The Company also has access to \$72.9 million in uncommitted short-term financing under lines of credit from various financial institutions. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At September 30, 2014, the Company had \$5.2 million outstanding under these short-term lines of credit. At September 30, 2014, the Company had total unused lines of credit related to the revolving credit agreement and the uncommitted short-term lines of credit of \$567.7 million.

At September 30, 2014, the Company held \$62.3 million of precious metals on consignment from several financial institutions. The consignment agreements allow the Company to acquire the precious metal at market rates at a point in time which is approximately the same time and for the same price as alloys are sold to the Company's customers. In the event that the financial institutions would discontinue offering these consignment arrangements, and if the Company could not obtain other comparable arrangements, the Company may be required to obtain third party financing to fund an ownership position in the required precious metal inventory levels.

At September 30, 2014, the majority of the Company's cash and cash equivalents were held outside of the United States. Most of these balances could be repatriated to the United States, however, under current law, would potentially be subject to U.S. federal income tax, less applicable foreign tax credits. Historically, the Company has generated more than sufficient operating cash flows in the United States to fund domestic operations. Further, the Company expects on an ongoing basis, to be able to finance domestic and international cash requirements, including capital expenditures, stock repurchases, debt service, operating leases and potential future acquisitions, from the funds generated from operations and amounts available under its existing credit facilities. The Company intends to retire or refinance the current portion of long-term debt due in the next year utilizing available cash flow, available commercial paper and the revolving credit facilities as well as other sources of credit.

There have been no material changes to the Company's scheduled contractual cash obligations disclosed in its Form 10-K for the year ended December 31, 2013.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Part 1, Item 1, Note 1, Significant Accounting Policies, to the Unaudited Interim Consolidated Financial Statements for a discussion of recent accounting standards and pronouncements.

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

There have been no significant material changes to the market risks as disclosed in the Company's Form 10-K for the year ended December 31, 2013.

Item 4 – Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal controls over financial reporting that occurred during the most recent quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings

Reference to Part I, Item 1, Note 15, Commitments and Contingencies, to the Unaudited Interim Consolidated Financial Statements.

Item 1A – Risk Factors

Except as noted below, there have been no significant material changes to the risk factors as disclosed in the Company's Form 10-K for the year ended December 31, 2013.

Item 2 – Unregistered Sales of Securities and Use of Proceeds

Issuer Purchases of Equity Securities

At September 30, 2014, the Company had authorization to maintain up to 34.0 million shares of treasury stock under the stock repurchase program as approved by the Board of Directors. During the quarter ended September 30, 2014, the Company had the following activity with respect to this repurchase program:

(in thousands, except per share amounts)

| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Cost of Shares Purchased | Number of Shares that May be Purchased Under the Share Repurchase Program |
|---|--|------------------------------------|--------------------------------------|--|
| July 1, 2014 to July 31, 2014 | 61.2 | \$ 47.41 | \$ 2,902.4 | 13,002.2 |
| August 1, 2014 to August 31, 2014 | 108.5 | 47.80 | 5,184.0 | 13,002.2 |
| September 1, 2014 to September 30, 2014 | 175.2 | 46.14 | 8,085.3 | 12,854.3 |
| | <u>344.9</u> | \$ 46.89 | <u>\$ 16,171.7</u> | |

Item 6 – Exhibits

| <u>Exhibit Number</u> | <u>Description</u> |
|-----------------------|--|
| 4.15 | United States Commercial Paper issuing and paying Agency Agreement dated as of November 4, 2014 between the Company and U. S. Bank N. A. |
| 31 | Section 302 Certification Statements |
| 32 | Section 906 Certification Statements |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Extension Labels Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the duly authorized undersigned.

DENTSPLY International Inc.

| | |
|--|-------------------------|
| /s/ <u>Bret W. Wise</u> | <u>October 29, 2014</u> |
| Bret W. Wise | Date |
| Chairman of the Board and Chief Executive Officer | |

| | |
|--|-------------------------|
| /s/ <u>Christopher T. Clark</u> | <u>October 29, 2014</u> |
| Christopher T. Clark | Date |
| President and Chief Financial Officer | |

ISSUING AND PAYING AGENT AGREEMENT

THIS ISSUING AND PAYING AGENT AGREEMENT (the "Agreement") is entered into as of November 4, 2014 by and between U.S. Bank National Association (the "Bank") with offices at 100 Wall Street, Suite 1600, New York, New York 10005 and DENTSPLY International Inc. (the "Company") regarding the following commercial paper program of the Company: \$500,000,000.00 CP Program of DENTSPLY International Inc.(hereinafter referred to as the "Program")

WITNESSETH:

WHEREAS, at the request of the Company, the Bank is prepared to (a) act as depository for the safekeeping of certain notes of the Company which may be issued and sold in the United States commercial paper market under the Program (the "Commercial Paper Notes"; such Commercial Paper Notes when issued in book-entry form being hereinafter referred to as "Book-Entry Commercial Paper Notes" and when issued in the form of certificated promissory notes being hereinafter referred to as "Certificated Commercial Paper Notes"), (b) as issuing agent on behalf of the Company in connection with the issuance of the Commercial Paper Notes, (c) as paying agent to undertake certain obligations to make payments in respect of the Commercial Paper Notes, and (d) as depository to receive certain funds on behalf of the Company, as set forth herein, and

WHEREAS, this Agreement will govern the Bank's rights, powers and duties as such depository, issuing agent and paying agent for the Commercial Paper Notes and the Company's rights and obligations in connection therewith.

NOW THEREFORE, for good and valuable consideration, the parties hereto agree as follows:

-12-

1. Appointment of Bank. The Company hereby appoints the Bank and the Bank hereby agrees to act, on the terms and conditions specified herein, as depository, and issuing and paying agent for the Commercial Paper Notes issued under the Program. The Commercial Paper Notes will be sold through such commercial paper dealers and/or placement agents as the Company shall have notified the Bank in writing from time to time (collectively, the "Dealers"). The Dealer(s) is/are currently Citigroup and JPMorgan Securities LLC.

2. Letter of Representations. The Company will promptly deliver to the Bank an executed version of the form of Letter of Representations (the "Letter of Representations") provided by The Depository Trust Company ("DTC"). The Company understands and agrees that such Letter of Representations when executed by the Company, the Bank and DTC shall supplement the provisions of this Agreement and that the Company, the Bank, and DTC shall be bound by the terms and provisions of the Letter of Representations, including any procedures and operational arrangements applicable thereunder.

3. Supply of Commercial Paper Notes.

(a) The Company will from time to time furnish the Bank with an adequate supply of

Commercial Paper Notes, which shall be Book-Entry Commercial Paper Notes and/or Certificated Commercial Paper Notes, as the Company in its sole and absolute discretion considers appropriate. If Certificated Commercial Paper Notes are to be issued, they shall be in the form provided by the Company, shall be serially numbered and shall have been executed by manual or facsimile signature of an Authorized Representative (as hereafter defined), but shall otherwise be uncompleted. Book-Entry Commercial Paper Notes shall be substantially in the forms attached to the Letter of Representations and shall be represented by one or more master notes ("Master Note" or "Master Notes") which shall be executed by manual or facsimile signature by an Authorized Representative in accordance with the Letter of Representations. Pending receipt of instructions pursuant to this Agreement, the Bank will hold the Certificated Commercial Paper Notes and Master Note(s) in safekeeping for the account of the Company or DTC, as the case may be, in accordance with the Bank's customary practice.

(b) Each Certificated Commercial Paper Note or Master Note delivered to the Bank shall be accompanied by a letter from the Company, as the case may be, identifying the Certificated Commercial Paper Note or Master Note(s) transmitted therewith, and the Bank shall acknowledge receipt of such Certificated Commercial Paper Note(s) or Master Note(s) on the copy of such letter or pursuant to some other form of written receipt deemed appropriate by the Bank at the time of delivery to the Bank of such Certificated Commercial Paper Note(s) or Master Note(s). Pending the issuance of Certificated Commercial Paper Notes as provided in Section 5 hereof, all Certificated Commercial Paper Notes and Master Note(s) delivered to the Bank shall be held by the Bank for the account of the Company or DTC, as the case may be, for safekeeping in accordance with the Bank's customary practice.

4. Authorized Representatives. With the delivery of this Agreement, the Company is furnishing to the Bank, and from time to time thereafter may furnish to the Bank, and shall furnish to the Bank upon the Bank's request, certificates ("Incumbency Certificates") of a responsible officer (a "Responsible Officer") of the Company certifying the incumbency and specimen signatures of officers or agents of the Company authorized to execute Commercial Paper Notes on behalf of the Company by manual or facsimile signature and/or to take other action hereunder on behalf of the Company (each an "Authorized Representative"); such Incumbency Certificate shall also specify the names of employees of Dealers who are authorized to give notices and/or issuance instructions to the Bank as provided herein (a "Dealer Representative"). Until the Bank receives a subsequent Incumbency Certificate of the Company, the Bank is entitled to rely on the last such Incumbency Certificate delivered to the Bank for purposes of determining the Authorized Representatives and Dealer Representatives. The Bank shall not have any responsibility to the Company to determine by whom or by what means a facsimile signature may have been affixed on the Commercial Paper Notes, or to determine whether any facsimile or manual signature resembles the specimen signature(s) filed with the Bank by a duly authorized officer of the Company. Any Commercial Paper Notes bearing the manual or facsimile signature of a person who is an Authorized Representative on the date such signature is affixed shall be binding on the Company after the authentication thereof by the Bank notwithstanding that such person shall have died or shall have otherwise ceased to hold his office on the date such Commercial Paper Note is countersigned or delivered to the Bank.

5. Completion, Authentication and Delivery of Commercial Paper Notes.

(a) In the case of Certificated Commercial Paper Notes, from time to time during the term of this Agreement and subject to the terms and conditions hereof, and upon the Bank's timely receipt of written, telecopy or telex instructions or notice transmitted directly to the Bank's computers or in such other manner as the Bank then employs as the Bank's normal business practice, not later than 12:30 pm New York City time on a day on which the Bank is open for business (a "Business Day"), from an Authorized Representative or a Dealer Representative, on the date of issuance of any Certificated

Commercial Paper Notes (in the case of instructions from an Authorized Representative, a copy of such instructions shall be sent to the Dealer Representative by said Authorized Representative), the Bank shall withdraw the respective Certificated Commercial Paper Notes from safekeeping and in accordance with the instructions so received, take the following actions with respect to each such Certificated Commercial Paper Note:

- i. date each such Certificated Commercial Paper Note the date of issuance thereof (which shall be a Business Day) and insert the maturity date thereof (provided that the Authorized Representative or Dealer Representative shall ensure that such date is a Business Day and that it shall not be more than 270 days from the date of issue) and the face amount (provided that Authorized Representative or the Dealer Representative shall ensure that such face amount is \$250,000 or integral multiples of \$1,000 in excess thereof) thereof in figures;
- ii. authenticate (by countersigning) each such Certificated Commercial Paper Note in the appropriate space provided thereon; and
- i. deliver in the Borough of Manhattan south of Chambers Street each such Certificated Commercial Paper Note to the Dealer, or the consignee, if any, designated by such Authorized Representative or Dealer Representative for the account of the Dealer.
- ii. the interest rate and applicable discount amount.

(b) In the case of Book-Entry Commercial Paper Notes, from time to time during the term of this Agreement and subject to the terms and conditions hereof, and upon the Bank's timely receipt of written, telecopy or telex instructions or notice transmitted directly to the Bank's computers or in such other a manner as the Bank then employs as the Bank's normal business practices, not later than 2:00 pm New York City time on a Business Day, from an Authorized Representative or a Dealer Representative, on the date of issuance of any Book-Entry Commercial Paper Notes (in the case of instructions from an Authorized Representative, a copy of such instructions shall be sent to the Dealer Representative by said Authorized Representative), the Bank shall give issuance instructions for the issuance of Book-Entry Commercial Paper Notes to DTC in a manner set forth in, and take other actions as are required by, the Letter of Representations. Instructions for the issuance of Book-Entry Commercial Paper Notes shall include the following information with respect to each Book-Entry Commercial Paper Note:

- i. the date of issuance of each such Book-Entry Commercial Paper Note (which shall be a Business Day);
- ii. the maturity date of each such Book-Entry Commercial Paper Note (provided that the Representative or Dealer Representative shall ensure that such date is a Business Day and that it shall not be more than 270 days from the date of issue); and
- iii. the face amount (provided that the Authorized Representative or the Dealer Representative shall ensure that such face amount is \$250,000 or integral multiples of \$1,000.00 in excess thereof) in figures; and
- iv. the interest rate and applicable discount amount.

(c) The Company understands that although the Bank has been instructed to deliver Commercial Paper Notes against payment, delivery of Commercial Paper Notes will, in accordance with the custom prevailing in the commercial paper market, be made before receipt of payment in immediately available funds. Therefore, once the Bank has delivered a Commercial Paper Note to a Dealer or its agent as provided herein, the Company shall bear the risk that a Dealer or its agent fails to remit payment for the Commercial Paper Note to the Bank. The Bank shall have no liability to the Company for any failure or inability on the part of the Dealer to make payment for Commercial Paper Notes. Nothing in this Agreement shall require the Bank to purchase any Commercial Paper Note or expend the Bank's own funds for the purchase price of a Commercial Paper Note or Commercial Paper Notes.

(d) Except as may otherwise be provided in the Letter of Representations, if at any time the Company instructs the Bank to cease issuing Certificated Commercial Paper Notes and to issue only Book-Entry Commercial Paper Notes, the Bank agrees that all Commercial Paper Notes will be issued as Book-Entry Commercial Paper Notes and that no Certificated Commercial Paper Notes shall be exchanged for Book-Entry Commercial Paper Notes unless and until the Bank has received written instructions from an Authorized Representative (any such instructions from a Dealer Representative shall not be sufficient for this purpose) to the contrary.

(e) It is understood that the Bank is not under any obligation to assess or review the financial condition or creditworthiness of any person to or for whose account the Bank delivers a Commercial Paper Note pursuant to instructions from an Authorized Representative or Dealer Representative or advise the Company as to the results of any such appraisal or investigation the Bank may have conducted on its own or of any adverse information concerning any such person that may in any way have come to the Bank's attention.

(f) It is understood that DTC may request the delivery of Certificated Commercial Paper Notes in exchange for Book-Entry Commercial Paper Notes upon the termination of DTC's services pursuant to the DTC Letter of Representations. Accordingly, upon such termination, the Bank is authorized to complete and deliver Certificated Commercial Paper Notes in partial or complete substitution for Book-Entry Commercial Paper Notes of the same face amount and maturity as requested by DTC. Upon the completion or delivery of any such Certificated Commercial Paper Note, the Bank shall annotate the Bank's records regarding the Master Note with respect to such Book-Entry Commercial Paper Notes to reflect a corresponding reduction in the face amount of the outstanding Book-Entry Commercial Paper Notes. The Bank's authority to so complete and deliver such Certificated Commercial Paper Notes shall be irrevocable at all times from the time a Book-Entry Commercial Paper Note is purchased until the indebtedness evidenced thereby is paid in full.

(g) If the Bank shall receive written or telecopy instructions (confirmed in writing in accordance with this Agreement) from the Company not to issue or deliver Commercial Paper Notes, until revoked in writing or superseded by further written instructions from the Company, the Bank shall not issue or deliver Commercial Paper Notes, provided, however, that notwithstanding contrary instructions from the Company, the Bank shall be required to deliver Commercial Paper Notes with respect to agreements for the sale of Commercial Paper Notes concluded by an Authorized Representative or Dealer Representative prior to receipt by the Authorized Representative or Dealer Representative of notice of such instructions from the Company, which the Authorized Representative or Dealer Representative shall be required to confirm to the Bank in writing prior to the Bank's delivery of the Commercial Paper Notes. For purposes of the preceding provision, the Bank may rely on written notice given or delivered to the Bank by an Authorized Representative or Dealer Representative as to whether any particular Commercial Paper Notes are to be issued in respect of such agreements concluded by such Authorized Representative or Dealer Representative, and the Bank shall have no obligation to make any other or further

investigation.

6. Proceeds of Sale of the Commercial Paper Notes. Contemporaneously with the execution and delivery of this Agreement, and for the purposes of this Agreement, the Bank will establish an account designated as the DENTSPLY International Commercial Paper Note Account (the "Note Account"). On each day on which a Dealer or its agent receives Commercial Paper Notes (whether through the facilities of DTC in the manner set forth in the Letter of Representations or by delivery in accordance with the provisions of this Agreement), all proceeds received by the Bank in connection with such sale shall be credited in immediately available funds to the Note Account. From time to time upon written instructions received by the Bank from an Authorized Representative, the Bank agrees to transfer immediately available funds from the Note Account to any bank or trust company in the United States for the Company's account. If the Bank chooses, in its sole discretion, to credit the Company's account before the Bank has collected funds for delivery of Commercial Paper Notes, it is understood that such credit shall be an advance to the Company to be promptly repaid to the Bank from the proceeds of sale of Commercial Paper Notes. If any such advance is not repaid on the day it is used, the Company shall repay such advance on the next business day together with interest thereon at the rate charged by the Bank for such advance (which rate shall be no less than the "Prime Rate"). As used in this Agreement, "Prime Rate" means the rate of per annum interest which U.S. Bank National Association ("USBNA") announces publicly or otherwise makes available to the public from time to time as its "prime rate" (currently calculated on the basis of the actual number of days elapsed over a year of 360 days) with any change in the "prime rate" to be effective on and as of the date of any change in said "prime rate". The Prime Rate and the calculation thereof may be established by USBNA in its sole discretion and is not necessarily the lowest rate of interest offered by USBNA to its most creditworthy customers. The Prime Rate is a variable or fluctuating rate which increases or decreases from time to time.

7. Payment of Matured Commercial Paper Notes.

(a) By 1:00 pm, New York time, on the date that any Commercial Paper Notes are scheduled to mature, the Company shall ensure that there shall have been transferred to the Bank for deposit in the Note Account immediately available funds at least equal to the amount of Commercial Paper Notes maturing on such date. When any matured Commercial Paper Note is presented to the Bank for payment by the holder thereof (which may, in the case of Book-Entry Commercial Paper Notes, be DTC or a nominee of DTC), payment shall be made from and charged to the Note Account to the extent funds are available in said account.

(b) Each Commercial Paper Note presented to the Bank for payment at or prior to 2:15 pm, New York City time, on any Business Day at or after the maturity date of such Commercial Paper Note shall be paid by the Bank on the same day as such presentation (or if presented after 2:15 pm, New York City time on any such Business Day, then on the next succeeding Business Day) to the extent funds are available in the Note Account.

8. Representations and Warranties of the Company. The Company hereby warrants and represents to the Bank, and, each request to issue Commercial Paper Notes shall constitute the Company's continuing warranty and representation, as follows:

(a) This Agreement is, and all Commercial Paper Notes delivered to the Bank pursuant to this Agreement will be, duly authorized, executed and delivered by the Company. The Bank's appointment to act for the Company hereunder is duly authorized by the Company.

(b) The issuance and delivery of the Commercial Paper Notes will not violate any state or

federal law and the Commercial Paper Notes do not require registration under the Securities Act of 1933, as amended.

(c) This Agreement constitutes, and the Commercial Paper Notes, when completed, countersigned, and delivered pursuant hereto, will constitute, the Company's legal, valid and binding obligations enforceable against the Company in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the rights of creditors generally and by general principles of equity.

(d) The Company is a corporation duly organized and validly existing under the laws of Delaware and no liquidation, dissolution, bankruptcy, windup or similar proceedings have been instituted with respect to the Company.

(e) The Company has, and at all relevant times has had, all necessary power and authority to execute, deliver and perform this Agreement and to issue the Commercial Paper Notes.

(f) The Company has taken all actions which are required for the authorization of the issuance of the Commercial Paper Notes, and for the authorization, execution, delivery and performance of this Agreement, and such actions do not require the approval or consent of any holder or trustee of any indebtedness or obligations of the Company.

(g) The issuance of Commercial Paper Notes by the Company (i) does not and will not contravene any provision of any governmental law, regulation or rule applicable to the Company, and (ii) does not and will not conflict with, breach or contravene the provisions of any contract or other instrument binding upon the Company.

(h) Each instruction given to the Bank in accordance with Section 5 hereof shall constitute a representation and warranty by the Company that the issuance and delivery of such Commercial Paper Note(s) have been duly and validly authorized by the Company

9. Reliance on Instructions. Except as otherwise set forth herein, the Bank shall incur no liability to the Company in acting hereunder upon telephonic or other instructions contemplated hereby which the Bank reasonably believed in good faith to have been given by an Authorized Representative or a Dealer Representative, as the case may be. In the event a discrepancy exists with respect to such instructions, the telephonic instructions as understood by the Bank will be deemed the controlling and proper instructions, unless such instructions are required by this Agreement to be in writing.

10. Cancellation of Commercial Paper Notes. Upon payment by the Bank of Certificated Commercial Paper Note(s) presented for payment, the Bank shall mark such Certificated Commercial Paper Note(s) as paid and (i) in due course cancel Certificated Commercial Paper Note(s) presented for payment and from time to time return such canceled Certificated Commercial Paper Notes to the Company, or (ii) destroy such Certificated Commercial Paper Notes(s) and deliver to the Company from time to time a destruction certificate identifying all Certificated Commercial Paper Notes destroyed since the issuance of the prior destruction certificate. After payment of any matured Book-Entry Commercial Paper Notes, the Bank shall annotate the Bank's records to reflect the face amount of Book-Entry Commercial Paper Notes outstanding in accordance with the Letter of Representations. Promptly upon the written request of the Company, the Bank agrees to cancel and return to the Company all unissued Certificated Commercial Paper Notes in the Bank's possession at the time of such request.

11. Notices; Addresses.

(a) All communications to the Bank by or on behalf of the Company or a Dealer, by writing, telecopy, telex or telephone, and which relates to the completion, delivery or payment of the Commercial Paper Note(s), are to be directed to Commercial Paper Operations at the address indicated in Section 11(b) below.

(b) Notices and other communications hereunder shall (except to the extent otherwise expressly provided) be in writing (which may be by facsimile) and shall be addressed as follows, or to such other address as the party receiving such notice shall have previously specified to the party sending such notice:

if to the Company, at: 221 W. Philadelphia St
Suite 60W
York, PA 17401
Attention: Assistant Treasurer
Facsimile No.: 717-849- 4486
Telephone No.: 717-849-4568

if to the Bank,

concerning the daily issuance of Commercial Paper Notes:

U.S. Bank National Association
100 Wall Street, 16th Floor
New York, NY 10005

Attention: Commercial Paper Operations

Facsimile No.: (212) 509-4529

Telephone No.: (212) 951-8508

concerning all other matters:

U.S. Bank National Association
100 Wall Street, Suite 1600
New York, NY 10005

Attention: Corporate Trust Administration

Facsimile No.: (212) 509-3384

Telephone No.: (212) 951-8561

(c) In any case where it is provided in this Agreement that a copy of any instruction, demand or other notice is to be delivered to a Dealer, such copy shall be delivered to the Dealer at the address set forth below by the same means as the original thereof shall have been given, provided that the failure of such copy to be given to any Dealer shall not invalidate or adversely affect the original thereof:

Dealer:

Notices shall be deemed delivered when received at the address specified above. For purposes of

this Section 11, "when received" shall mean actual receipt (i) of an electronic communication by telecopier or issuance system specified in or pursuant to this Agreement; or (ii) of an oral communication by any person answering the telephone at the office of the individual or department specified in or pursuant to this Agreement; or (iii) of a written communication hand-delivered at the office specified in or pursuant to this Agreement.

12. Liability. Neither the Bank nor the Bank's agents shall be liable for any act or omission hereunder, except in the case of gross negligence or willful misconduct as described in Section 13 herein. The Bank's duties and obligations shall be determined by the express provisions of this Agreement, and the Letter of Representations (including the documents referred to therein), and the Bank and the Bank's agents shall be responsible for the performance of only such duties and obligations as are specifically set forth herein and therein, and no implied covenants shall be read into any such document against the Bank or the Bank's agents. Neither the Bank nor the Bank's agents shall be required to ascertain whether any issuance or sale of Commercial Paper Note(s) (or any amendment or termination of this Agreement) has been duly authorized or is in compliance with any other agreement to which the Company is a party (whether or not the Bank or any such agent is a party to such other agreement).

13. Indemnity. The Company agrees to indemnify and hold the Bank, the Bank's employees and any and all of the Bank's officers and agents harmless from and against any and all losses, liabilities (including liabilities for penalties), actions, suits, judgments, demands, damages, costs and expenses of any nature (including, without limitation, attorneys' fees and expenses) arising out of or resulting from this Agreement or the transactions or activities contemplated hereby or the exercise of the Bank's rights and/or the performance of the Bank's duties (or those of the Bank's agents and employees) hereunder; provided, however that the Company shall not be liable to indemnify or pay the Bank or any of the Bank's officers or employees with respect to any loss, liability, action, suit, judgment, demand, damage, cost or expense that results from or is attributable to the Bank's gross negligence or willful misconduct or that of the Bank's officers or employees. The foregoing indemnity includes, but is not limited to, (a) any action taken or omitted to be taken by the Bank or any of the Bank's officers or employees upon written, telecopy, telephonic or other electronically transmitted instructions (authorized herein) received by the Bank from, or believed by the Bank in good faith to have been given by, the proper person or persons, (b) the Bank's improperly executing or failing to execute any instruction because of unclear instructions, failure of communications media or any other circumstances beyond the Bank's control, and (c) the actions or inactions of DTC. The provisions of this Section 13 shall survive (i) the Bank's resignation or removal hereunder and (ii) the termination of this Agreement. In no event shall the Bank be liable for special, indirect or consequential damages.

14. Termination.

(a) This Agreement may be terminated at any time by either the Bank or the Company by 15 days' prior written notice to the other, provided that the Bank agrees to continue acting as issuing and paying agent hereunder until such time as the Bank's successor has been selected and has entered into an agreement with the Company to that effect. Such termination shall not affect the respective liabilities of the parties hereunder arising prior to such termination.

(b) If no successor has been appointed within 30 days, then the Bank have the right to petition a court of competent jurisdiction for the appointment of a successor issuing and paying agent hereunder. The Bank shall be reimbursed for any and all expenses in connection with any such petition and appointment.

(c) On the Business Day following the date of termination of this Agreement, the Bank shall

destroy all Certificated Commercial Paper Notes in the Bank's possession and shall transfer to the Company all funds, if any, then on deposit in the Note Account. The Bank shall promptly notify the Company of all Certificated Commercial Paper Notes so destroyed.

15. Amendments and Modifications. No amendment, modification or waiver of any provision of this Agreement, nor any consent to any departure by any party from any provision hereof binding upon such party, shall be effective unless the same shall be in writing and signed by all the parties hereto.

16. Binding Effect; Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto, their respective successors, including successors by merger, and assigns; provided, however, that no party hereto may assign any of its rights or obligations hereunder, except with the prior written consent of all the other parties hereto.

17. Governing Law.

(a) This Agreement shall be governed and construed in accordance with the laws of the State of New York applicable to contracts made and performed in the State of New York and, to the extent applicable, operating circulars of the Federal Reserve Bank, federal laws and regulations as amended, New York Clearing House rules and, to the extent not otherwise inconsistent with this Agreement, general commercial bank practices applicable to commercial paper issuance and payment.

(b) Each party irrevocably and unconditionally submits to the exclusive jurisdiction of the United States Federal courts located in the Borough of Manhattan and the courts of the State of New York located in the Borough of Manhattan.

18. Execution in Counterparts. This Agreement may be executed in any number of counterparts; each counterpart, when so executed and delivered, shall be deemed to be an original; and all of which counterparts, taken together, shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

19. Headings. Section headings used in this Agreement are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.

20. Compensation and Expenses. The Company shall pay the Bank from time to time following the execution of this Agreement reasonable compensation for all services rendered by the Bank hereunder as agreed between the Bank and the Company. The Company shall reimburse the Bank upon the Bank's request for all expenses, disbursements and advances incurred or made by the Bank in accordance with any provision of this Agreement (including the reasonable compensation and the expenses and disbursements of the Bank's agents and counsel) except any expense or disbursement attributable to the Bank's gross negligence or willful misconduct.

21. Miscellaneous.

(a) No implied covenants or obligations of or against the Bank are to read into this Agreement or any other agreement. No provision of this Agreement shall require the Bank to risk the Bank's own funds or otherwise incur any financial liability in the performance of any of the Bank's duties hereunder or in the exercise of any of the Bank's duties hereunder or in the exercise of any of the Bank's rights and

powers hereunder. If the Bank makes a deposit, payment or transfer of funds before the Bank receives immediately available funds, such deposit, payment or transfer shall represent an advance by the Bank to the Company to be repaid from such funds or by the Company in the event that such funds are not promptly received by the Bank. It is intended that such advance be for no longer than 24 hours. Interest on each such unpaid advance shall be at the rate charged by the Bank for such advance (which rate shall be no less than USBNA's Prime Rate). The Company shall ensure the prompt reimbursement to the Bank of any such advance (including the interest thereon).

(b) The Bank may consult with counsel, and any advice or written opinion of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted to be taken by the Bank, in the absence of bad faith, gross negligence or willful misconduct on the Bank's part, in reliance on such advice or opinion.

(c) The Bank makes no representation as to, and shall have no responsibility for, the correctness of any statement contained in, or the validity or sufficiency of, this Agreement or any documents or instruments referred to in this Agreement or as to or for the validity or collectibility of any obligation contemplated by this Agreement. The Bank shall not be accountable for the use or application by any person of disbursements properly made by the Bank in conformity with the provisions of this Agreement.

(d) The Bank may rely and shall be protected in acting upon any document or writing presented to the Bank hereunder and in good faith believed by the Bank to be genuine and to have been signed and presented by an authorized person or persons.

(e) In no event shall the Bank be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Bank shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

IMPORTANT INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT

The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. Patriot Act, the Bank, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Bank . The parties to this Agreement agree that they will provide the Bank with such information as it may reasonably request in order for the Bank to satisfy the requirements of the U.S.A. Patriot Act.

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the day and year first above written.

DENTSPLY International Inc.

Name: _____
William E. Reardon, VP & Treasurer

Andrew M. Smith, Assistant Treasurer

Date: _____

**U.S. BANK NATIONAL
ASSOCIATION**

Signature

Authorized Officer's

Name: _____

Title: _____

Date: _____

Section 302 Certifications Statement

I, Bret W. Wise, certify that:

1. I have reviewed this Form 10-Q of DENTSPLY International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 29, 2014

/s/ Bret W. Wise
Bret W. Wise
Chairman of the Board and
Chief Executive Officer

Section 302 Certifications Statement

I, Christopher T. Clark, certify that:

1. I have reviewed this Form 10-Q of DENTSPLY International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 29, 2014

/s/ Christopher T. Clark
Christopher T. Clark
President and
Chief Financial Officer

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DENTSPLY International Inc. (the "Company") on Form 10-Q for the period ending September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), We, Bret W. Wise, Chairman of the Board of Directors and Chief Executive Officer of the Company and Christopher T. Clark, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge and belief:

- (1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of the date of the Report.

/s/ Bret W. Wise
Bret W. Wise
Chairman of the Board and
Chief Executive Officer

/s/ Christopher T. Clark
Christopher T. Clark
President and
Chief Financial Officer

October 29, 2014